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ABSTRACT 
 
 
Hip fracture is the most common reason for admission to an acute orthopaedic ward, the 
majority can be related to osteoporosis and are more frequent above the age of 50 years, in women. 
Higher mortality and morbidity rates are the major consequences of hip fractures, higher amongst 
men. With the aging of the population the number of hip fractures tend to increase stretching the 
available resources.  
The objectives of this study are: evaluate the trends of hip fracture incidence in Portugal and 
identify possible determinants, obtaining a quality measurement before the event and a risk 
adjustment for the treatment of hip fractures, as well as a characterization of the National Health 
Service (NHS) in terms of the treatment for this pathology, assessing the quality improvement after 
the fracture. 
Data from the National Hospital Discharge Database was used. Mandatory for all Portuguese 
public hospitals since 1997, it compiles clinical and demographic information on all discharges. 
Hospitalizations from 1
st
 January 2000 to 31
st
 December 2008, caused by hip fractures (low energy, 
patients over 49 years of age) were selected and used as data in all the partial studies. National 
Authority of Medicines and Health Products (INFARMED) provided the data regarding the 
osteoporotic medication sales. Population data used to calculate incidence rates was obtained in the 
Statistics Portugal (INE). Generalized Additive (GAM) and Generalized Linear Models (GLM) 
were used in the assessment of hip incidence trend. Age-Period-Cohort Models and GAM were 
used to assess the period and cohort effect. A multilevel Bayesian model was used to obtain a risk 
adjustment, provide a comparison between providers and obtain a temporal trend on the probability 
of dying during hospitalization for hip fracture treatment. 
During the study period were selected 77,083 hospital admissions (77.4% women) caused by 
low energy, in patients over 49 years-age, mean age (standard deviation (SD)) at admission was 
81.0 (SD 8.5) years old versus 78.0 (SD 10.1) (p-value < 0.0001) for women and men respectively. 
A turning point in 2003 was identified in the trend of hip fracture incidence in women. This abrupt 
decrease is compatible with the pattern of bisphosphonates sales. A cohort effect was identified 
both for men and women, the pattern highlighted changes in risk of hip fracture, on important 
points in the history of Portugal, statistical significant around 1930.  
The probability of dying during a hospitalization to treat hip fractures was associated with 
individual characteristics’, women presented lower probability compared to men, even after 
adjustment for age, severity, treatment, time to surgery, length of stay, transfers (yes/no), hospital 
and area characteristics. No hospital effect was identified, hospitals that treat more than 50 hip 
fractures per year, have the same overall effect on the probability of dying.
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The overall probability during the period did not presented changes. However some hospitals 
presented improvement.  
 This study provided an extensive analysis on the treatment of hip fractures, during a period 
of 9 years. The results are innovative and highlight possibilities of improvement as well as valuable 
information to health authorities. 
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RESUMO 
 
 
As fracturas do fémur proximal são a causa mais comum de admissão nos serviços de 
ortopedia, a sua maioria está relacionada com a osteoporose e são mais frequentes acima da idade 
de 50 anos, nas mulheres. As elevadas taxas de mortalidade e morbilidade são a maior 
consequência das fracturas do fémur proximal, apresentando-se mais altas entre os homens. Com o 
envelhecimento da população o número de fracturas tende a aumentar, acarretando uma elevada 
utilização dos recursos existentes. 
Os objectivos este estudo são: a avaliação da tendência das taxas de incidência de fracturas 
do fémur proximal em Portugal e a identificação de possíveis determinantes da tendência, obtendo 
uma medida de qualidade antes da fractura. A obtenção de um ajuste de risco para o tratamento das 
fracturas, assim como uma caracterização do Serviço Nacional de Saúde (SNS), avaliando a 
qualidade do tratamento após a fractura. 
Os dados da Base de Dados Nacional de Grupos de Diagnóstico Homogéneo relativos a altas 
hospitalares, contendo informação clínica e demográfica foram usados. As hospitalizações de 1 de 
janeiro de 2000 a 31 de dezembro de 2008, causadas por fracturas do fémur proximal (baixa 
energia e pacientes com idade superior a 49 anos) foram selecionadas e usadas nos estudos parciais. 
Os dados relativos à venda de medicamentos anti-osteoporóticos foram fornecidos pelo 
INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde. O Instituto Nacional de 
Estatística –INE foi a fonte para os dados populacionais que serviram para o cálculo das taxas de 
incidência. Modelos Aditivos e Lineares Generalizados (GAM e GLM) foram usados para 
avaliação das tendências da incidência de fracturas. Modelos Idade-Período-Coorte e GAM foram 
usados para a avaliação da existência de efeitos período e coorte. Um modelo Bayesiano 
hierárquico foi usado para obter o ajuste de risco, comparar entre hospitais e obter a tendência 
temporal da probabilidade de morrer durante a hospitalização para tratamento da fractura do fémur 
proximal. 
Durante o período em estudo foram seleccionadas 77,083 admissões hospitalares (77.4% 
mulheres) com diagnóstico de fractura do fémur proximal, causada por baixa-energia e em doentes 
com mais de 49 anos de idade, idade média na admissão (desvio padrão DP) foi 81.0 (DP 8.5) 
versus 78.0 anos (DP 10.1) (valor-p <0.0001) para mulheres e homens respectivamente.  
Uma alteração brusca foi identificada na tendência das fracturas nas mulheres, no ano de 
2003 compatível com o padrão de vendas de bisfosfonatos. Foi identificado um efeito coorte que 
reflecte alterações de risco nos principais momentos históricos da história de Portugal, 
estatisticamente significativo em volta de 1930.
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A probabilidade de morrer durante a hospitalização para tratamento da fractura do fémur, 
proximal está associada com as características individuais dos indivíduos, sendo que as mulheres 
mesmo depois do ajuste apresentam um valor mais baixo quando comparado com o dos homens. 
Não foi identificado nenhum efeito do hospital, hospitais que tratam mais de 50 fracturas por ano, 
têm um efeito semelhante na probabilidade de morrer. A tendência temporal da probabilidade de 
morrer no hospital, não sofreu alterações durante o período de estudo. No entanto, alguns hospitais 
mostraram melhorias. 
Este é um estudo exaustivo do tratamento de fracturas do fémur proximal, durante um 
período de 9 anos. Os resultados são inovadores, assinalam possibilidades de melhoria e 
apresentam informações importantes para as autoridades de saúde. 
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Motivation 
The fractures that occur in the proximal part of the femur are also designated hip fractures 
and can be further classified according to their location; figure 1 is illustrative of the different 
classification of hip fractures [1]. The majority of hip fractures occur in individuals with fifty or 
more years-old, mainly due to the reduction of bone mineral density that may lead to osteoporosis 
[2]. Better conditions of life and healthcare led to an increase of life expectancy in European 
countries [3], which consequently leads to a higher number of population at risk of sustaining a hip 
fracture. According to the Statistics Portugal-INE (Instituto Nacional de Estatística), the Portuguese 
population over the age of 64 suffered an increase of 18.69% from 2001 to 2011 [4]. 
 
 
Figure 1: Classification of hip fractures. Reproduced from Parker and Johansen, 2006 [1] 
 
Hip fracture is the most common reason for admission to an acute orthopaedic ward [1] and 
with the aging of the population the number of hip fractures tend to increase stretching the 
available resources[5, 6].  In addition, osteoporotic hip fractures present high mortality and 
morbidity rates [2, 7]. In a period of three years (2000 – 2002) it were treated in hospitals of the 
National Health System (NHS) 36, 846 cases representing a cost of about 185 hundred thousand 
Euros. From these patients about 5.6% died while in the hospital [8]. The morbidity and mortality 
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rates after discharge are not easy to assess because the majority of patients recover at home and in 
Portugal it is not possible to have a database linkage between health databases. However a cohort 
study conducted in one of the major hospitals in Portugal, during one year, reported at one year 
follow-up a mortality rate of 23 and 37 per 100 patients in women and men, respectively and that 
30% of the patients were in bed confinement [9]. There are studies that report that 80% of women 
aged 75 years and older preferred death over the loss of independence after the fracture [10].  
The interest in quality of health care has been increasing in most health care systems around 
the world. However, there are countries that still do not assess the quality of care delivered to their 
citizens [11].  
 Quality of care can be defined as “the degree to which health services for individuals and 
populations increase the likelihood of desire health outcomes and are consistent with current 
professional knowledge” [12] cited by [11]. One way to assess quality of care is through the use of 
indicators, that can be defined as “measurements tools, screens, or flags that are used as guides to 
monitor, evaluate, and improve the quality of patient care, clinical support services and 
organizational function that affect patient outcome” [13] cited by [11]. Clinical indicators can be 
related to several steps in health care process; therefore there can be structure, process and outcome 
indicators [11, 14].  Structure indicators are related to the attributes of the material resources and 
organizational structure. Process indicators are related to the actions in giving and receiving care 
and finally outcome indicators are related to the description of the effects of care [11, 14]. The 
outcome of care results from a variety of factors that are not necessarily linked to the quality of 
care received (e.g. severity of the patient). It is therefore important to adjust the indicators for 
possible confounders to obtain a fair result.  
Clinical indicators should measure areas that contribute with high mortality and morbidity, 
with high costs in care and that have potential for improvement [15, 16]. Hip fracture is a clinical 
area that presents all those characteristics.  
This study aimed to assess preventive treatment as well as the actual treatment received after 
a hip fracture.  
Preventive treatment, by definition can incorporate a number of different actions that aim to 
promote and maintain health and prevent disease and disability [17]. Fall prevention, which would 
be one of the most effective preventive actions [18] is difficult to assess in Portugal, nationwide, 
because there is not a global strategy or a systematic approach to this preventive measure. 
Pharmacological treatment is also considered a vehicle to prevent fractures in the elderly, with 
highest clinical and cost effective results when targeted at those who are at higher risk [18]. These 
preventive actions would reflect on hip fracture incidence and Portugal would have a measure of 
preventive treatment for hip fracture.  
However, the trend of hip fracture rate can be driven by other factors not directly related to 
the specific treatment of hip fractures. General health status of the population, life and nutritional 
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conditions, changes in body mass index [18], could serve as confounders to assess the underlying 
quality of treatment, therefore it is necessary to address the problem from several perspectives to 
have a better understanding of the indicator. 
After the occurrence of the hip fracture, there is established evidence that surgical treatment 
is better than conservative [19]. Patients with hip fracture are always hospitalized for treatment, 
even if the treatment received in the hospital will be conservative, which maybe the result of a 
balance decision of either providers or the patient or family. As mentioned previously the non-
existence of database linkage between different health databases in Portugal is a limitation to the 
outcome measures that can be assessed. In-hospital fatality is available and has been used as 
outcome measures for hip fracture treatment. The interpretation of the care provided to hip fracture 
is based on the three-way approach to quality proposed by Donabedian [20, 21], where quality of 
care should be evaluated using structure, process and outcome indicators, stringed because “good 
structure increases the likelihood of good process, and good process increases the likelihood of a 
good outcome” Donabedian (1988). In this perspective better outcomes are a result of both patient 
characteristics but also procedures and resources associated to providers. 
In a previous study, conducted between 2000 and 2002 [8], there were 92 different hospitals 
with discharges related to the treatment of hip fractures, in figure 2 their location is displayed with 
a circle proportional to the number of cases treated (it were excluded hospitals with less than 5 
cases). In this figure is also displayed the flux of patients from place of residence to the hospitals. 
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Figure 2: Map of flux of patients with hip fracture: place of residence to hospital of 
admission, period 2000-2002. Reproduced from Alves, 2005 [8] 
 
Hospitals will differ not only in the amount of patients treated, which can be a measure of 
their expertise, but also in the resources and actual procedures. Therefore in order to have a feasible 
indicator for the treatment of hip fracture in Portugal it is important to consider these variations. 
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Objectives 
The main objectives of this work are: evaluate the trends of hip fracture incidence in 
Portugal and identify possible determinants, obtaining a quality measurement before the event) and 
a risk adjustment for the treatment of hip fractures, as well as a characterization of the National 
Health Service (NHS) in terms of the treatment for this pathology, assessing the quality 
improvement after the fracture. 
The following research questions need to be attended: 
What is the time trend of hip fracture incidence? 
What are possible determinants for such trend? 
Interventions? 
Cohort effect? 
What are the determinants of in-hospital fatality (outcome indicator)? 
Economic? 
Structure (human and material resources available)? 
Patient’s medical status? 
Procedures? 
 Are there differences in the quality of hip fracture treatment in Portuguese hospitals? 
If the hospitals had the same economical, structural, complexity of patients and 
preformed the same procedures what would be their fatality experience for patients 
with hip fractures related hospitalizations? 
Are there time trends of in-hospital fatality following a hip fracture? 
 
The strategy will be to divide the focus of the study in two parts. The first part will address 
the determinants of incidence as a way to achieve the understanding of treatment before the 
fracture event. The second part will address the determinants of an unfavorable outcome: in-
hospital fatality as a way to achieve the understanding of treatment after the fracture event. 
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Thesis Synopsis 
The work presented in this thesis is organized in the following chapters: 
Chapter II, state of art, provides a definition of clinical indicators, the importance of risk 
adjustment and a general overview of the existent indicators for the treatment of hip fractures in 
several countries. Chapters III to IV present the four scientific articles produced in the context of 
this thesis. 
Chapter III and IV contain the research conducted to address the questions related to the 
treatment before the fracture event (preventive treatment). First it was conducted a temporal study 
of hip fracture incidence in Portugal, by sex and age group that revealed an abrupt turning point 
compatible with pharmacological interventions existent in Portugal. The evolution of medication 
related to osteoporosis was assess during the same period and the number of bisphosphonates 
packages sold seem to be plausible explanation for the turning point observed in age standardized 
incidence rates in women. Chapter III describes this study. 
Chapter IV describes the work conducted in order to separate the effect of age, period and 
cohort in the trend of hip fracture incidence. The study revealed that in fact the year of diagnose 
had a non-linear effect on hip fracture incidence  rates, for women, with a turning point, regardless 
of age and cohort effect. And identified a cohort effect that presented alterations in all the major 
moments of the History of Portugal, suggesting a long-term effect on population health of the 
political and economic actions suffered in the life-time of the patient.  
The work developed in order to understand the quality of treatment after the fractures is 
described in Chapter V and VI. First, and through a systematic review, some macro-economic 
variables were explored has determinants for in-hospital fatality rates, as described in Chapter V. 
In Chapter VI, it is described the adjustment performed as well as the characterization of the 
SNS regarding the outcome following a hip fracture. The probability of dying while hospitalized, 
for the treatment of a hip fracture, was manly associated with individual characteristics’. No 
hospital effect was identified, however some hospitals presented some improvement. 
Finally, chapter VII provides a general discussion and conclusions from the work develop in 
this thesis, and some perspectives for further research work. 
After each chapter, a list of the bibliographic references in that chapter is presented. 
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Clinical Indicators for quality improvement – the case of hip 
fractures 
 
 
Introduction 
The economic difficulties that our society is facing raise the discussion of quality of care. In 
health, more than any other field, it is vital to achieve high results, meet high standards, reach the 
greatest effectiveness and nowadays, more than ever, with the lower costs. In order to assure that 
the results are met, the assessment measures should be effective. Clinical indicators work as tools 
to flag situations that potentially need intervention. 
Hip fractures implications can be measured at individual or societal level. The effect on a 
patient can go from loss of previous functional status to a more dramatic outcome of death. 
However, there are also burdens to society, a surgery to treat a hip fracture is a costly procedure, 
followed by a rehabilitation that may require specialized help or permanent assistance. Good 
practices are desirable, the protocols should be followed however the routine producers should be 
consistently measured and object of systematic analysis, as they may lead to improvement on 
desirable outcomes and effectiveness of treatment. 
 
Clinical indicators. What are they? And why use them? 
Medical care was considered, for a long time, a simple process between the physician and 
the patient. The treatment process did not seem influenced by external factors, depending only 
upon biological and psychological variables [1]. With the generalization of health care and the 
exponential rise of information available the concept of health, itself, suffered alterations and gain a 
wider amplitude, as is currently viewed as "a state of complete physical, social and mental well-
being, and not merely the absence of disease or infirmity", World Health Organization 1946[2]. 
Therefore, it is recognized that the state of health is influenced not only by health related factors, 
such as genetic (intrinsic) or promotional aspects (extrinsic), but also by external elements such as 
economic or social factors [2]. Hence, the process began to be understood as multidimensional, 
comprising all stakeholders: practitioners, patients and community.  
The new paradigm of health and the flow of information led, inevitably, to question the 
variations in clinical practice [1] and how to measure it. Since the medical care is now considered 
multidimensional [3, 4], so should  be the assessment, and this is the basic idea behind the system-
based framework of structure, process and outcome, first proposed by Donabedian [3, 5] for quality 
of care assessment. This three-way approach sets the entire process of health care divided into parts 
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stringed because “good structure increases the likelihood of good process, and good process 
increases the likelihood of a good outcome” Donabedian (1988). 
The measurement is accomplished through the use of clinical indicators “measurements 
tools, screens, or flags that are used as guides to monitor, evaluate, and improve the quality of 
patient care, clinical support services and organizational function that affect patient outcome” [6] 
cited by [4] that give tangible reflections of health care. Structure indicators are related to the 
attributes of the material resources and organizational structure. Process indicators are related to the 
actions in giving and receiving care and finally outcome indicators are related to the description of 
the effects of care [4, 7]. 
Clinical relevant indicators are the ones that apply to an health issue that contributes 
significantly to morbidity or mortality, is associated with high utilization rates or present high 
treatment costs [8]. Ideally, the health issue should have potential for improvement, however any 
act of care can have quality assessed, and with the cost constrains it is important to do so, to assure 
the necessary structural means.  
 
In order to implement indicators, it is necessary  very specific criteria and it is important to 
understand every action under the three aspects of quality of care. A thorough detail provides a 
better chance to achieve a feasible indicator that truly translates care. Indicators measuring 
structure quality represent organisational factors where care takes place [3] and can be classified in 
physical and staff characteristics [9]. The facilities, equipment, economic resources and the 
organisational structures underlying all these are grouped under the physical characteristics; 
number and qualification of personnel are under the staff characteristics, however the 
organisational aspects of these fall into the first group [9]. These aspects do not assure the quality 
of care but provide an opportunity to receive it. 
The real actions of giving and receiving health are represented by process indicators [3] that 
similar to structure can also be divided into two groups clinical and inter-personal care. In the first 
category are actions related to the biomedical aspects of healthcare, more technical actions: like 
activities involved both with diagnosis and treatment, including the information retrieved by 
clinical history and that obtained by examinations as well as the appropriateness of therapeutic 
procedures based on such information. In the second category are the aspects related with 
interactions between patients and care givers [9]. Having these marked differences, indicators from 
the two categories must have different scientific areas in the background; the knowledge behind the 
indicators regarding clinical aspects must derive from health sciences, whereas the indicators 
regarding interpersonal aspects should derive from social/ behavioural sciences [3].  
To better obtain a process indicator it is compulsory to look at the strength of the scientific 
evidence and the cost-effectiveness of the indicator process [8], there are many indicators that 
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follow evidence based guidelines [10]. Scientific evidence may be assessed through published 
literature or directly through organizations that have that mission, like the Cochrane Collaboration. 
This organization sets to provide the best evidence for health care [11], trough the preparation, 
update and promotion of reviews that will help healthcare providers to set guidelines, policy 
makers to promote indicators, and patients to be a part of the decisions. 
Some areas of interest may produce more precise indicators than others, number of hospital 
beds (structure indicator) is a direct measure in contrast to scales of patient satisfaction (process 
indicator) [12], however both are important and none should be disregarded.  
Finally, outcome measures, which are related to the effect on population and patients health 
status and can be also divided into two categories: health status and user evaluation [9]. Recovery, 
restoration of functional status or survival can be considered health status related; Improvement of 
patients knowledge, changes in patients behaviour or patients satisfactions can be considered a 
wider class of health status [3] falling into user evaluation category. Whilst it is possible to report 
the indicators considering a positive approach, the majority of studies published in the literature use 
the negative side of these standards as measures [13] such as mortality, or fatality rates. Reason for 
this choice may be related to the objectivity of the measure “death of patient” comparing to others 
like “satisfaction of patient”. It is easier and less subject to errors to assess the death rather than the 
restoration of physical status. 
 
The multidimensional core of health and health care should lead stakeholders to the use of 
several indicators, for all three dimensions. However, these do not invalidate the discussion to set a 
hierarchy between dimensions. The most sensitive one regards process versus outcome indicators.  
Outcome indicator is the ultimate health indicator as it is a reflection of all steps in care [3], 
including those that are harder to measure, such as technical expertise [14], this however may also 
be pointed as a negative aspect as it may blind parts that need immediate interventions. Another 
positive aspect of using outcome measures is the availability of data, at least for the calculation of 
simple rates. Summing to the negative aspects are the possible lag time between outcomes and 
interventions, as it may take some years following treatment to develop the outcome [9] as well as 
the dependency upon other factors such as patient characteristics [10]. Moreover, differences in 
outcome measures can also be a reflection of differences in measurement, it is therefore important 
to clearly define cases, outcome and risk factors [14], or even chance, as it may be influenced by 
number of cases and frequency with which the outcome occurs.   
A number of outcome indicators are based on rates, only valid for comparison if based upon 
a relatively large denominator, overcoming the “Problem of Small Numbers”. This problem is 
described as the random fluctuation that occurs on rates, by the variation of the numerator in a few 
cases when the denominator is not sufficient large. This problem may occur when calculating some 
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indicators in small hospitals and aggregation of hospitals or time aggregation may not be a cleaver 
solutions, because it crashes the possibility of identification of good and bad practices [15]. A 
solution may be the use of several indicators at a time, namely the use of some that does not take 
the form of a rate, for instance, Length of Stay (LOS). 
Process indicators on the other hand are only valid if they predict the outcome [9, 10], but 
can instantly be produced following the care, and therefore preventive measures upon bad actions 
can be immediately taken, instead of waiting for an outcome to be produced. Another positive 
aspect when using process indicators is the fact that variations in the indicator are more dependent 
upon differences in care and are easier to interpret [14]. In many cases these indicators are related 
to actions such as “nutritional status assessed” rather than “hospital specific mortality rate”.   
Accounting for all these positive and negative aspects and proposed solutions, ideally it is 
best to include in any assessment system indicators from the three dimensions, as they are 
complementary and maybe easier to get a correct interpretation of the findings [3].  
 
The use of indicators provides a chance to understand quality in health care, at several levels. 
Their use is important to use as aim to translate and produce knowledge [14], namely: 
 
 Improve the quality of care of a health care facility; 
 Identify poor performers to protect public safety; 
 Provide consumer information to facilitate choice of health care provider; 
 Inform policymakers at a regional or national level. 
 
In order to meet their goals, indicators should be thoroughly analysed and all possible bias 
controlled. The first string in the chain: structure is less subject to external influence of other 
variables; however both process and outcome indicators are disturbed by a variety of variables that 
have nothing to do with the quality of care received. The severity of the patients treated is one 
aspect that may affect the final measure and may not lead to linear conclusions, of better care 
leading to better measure in the indicator; a unit may be performing worse than a similar just 
because the patients treated there had a more complicated situation, and not because the quality of 
care was worse. This fact may lead to erroneous conclusions, as the final measure may be biased. 
The adjustment of the indicators plays, therefore, an important role in the final achievement of fair 
and reliable measures. 
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The importance of risk adjustment 
The use of indicators to compare efficiency and costs across providers or to compare 
internally the patient outcome to motivate quality improvement within a provider is to be done 
carefully. Situations where a better position regarding the result of an indicator represent a better 
care are not straightforward, since indicators are influenced by other aspects aside from quality of 
care. Some indicators are more subject to the influence of external factors than other; namely 
outcome indicators are more sensitive than process indicators to other covariates [16], so the 
following description is centred on outcome indicators. Outcome measures may be considered a 
function of quality of care and other covariates, as proposed by Iezzoni, 2003 [17],  
 
Outcomes = f (intrinsic patients related risk factors, treatment effectiveness, quality of care, 
random chance) 
 
The purpose of risk adjustment is to remove sources of variation leaving residual differences 
to reflect the quality of care [18]. Risk adjustments can be performed considering different kinds of 
risk: clinical outcomes, resources used or patient centred outcomes. The first accounts for outcomes 
such as death or physical status, the second for costs or length of stay and finally the third account 
for satisfaction or expectations[19] .  
There are some risk-adjustment methods already in use [18, 19] that differ firstly on the risk 
accounted for, some are focused in costs, others in clinical outcomes, others offer multiple versions 
for different outcomes [19]. A risk adjustor may predict one outcome but fail to predict another, it 
is therefore important to choose an adjustor design for the outcome [18, 19]. 
Risk adjustment may require additional data [8] than the one necessary to calculate the 
indicator, because the risk of an outcome is, as mentioned before, affected by several patient 
characteristics, including: demographic characteristics (age, sex, race and ethnicity), clinical factors 
(such as principal diagnosis and its severity, co-morbid illnesses), socioeconomic factors (such as 
cultural beliefs and behaviours, economic resources), health related behaviours and activities (such 
as tobacco use, alcohol consumptions) and attitudes and perceptions (overall health status and 
quality of life, preferences and expectations for health care services) [18, 20]. Adjusting for all 
characteristics is considered neither possible nor necessary [19]. The nature of data to be included 
in the adjustor, whether administrative, clinical or surveys, have a deep influence on the design, 
e.g, if a large dataset is available than indicators can be empirically developed in opposition to 
others that are solely based upon clinical judgment [19].  
As mentioned, adjusting for all variables is impossible and unnecessary, the choice of what 
characteristics should be used to adjust is dependent of the outcome, however there are a few that 
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are almost universal. Age is a common variable in the adjustment, since it has almost always an 
effect, even after adjusting for other variables usually highly correlated like presence of chronic 
diseases[20]. Age may cause providers to question some forms of treatment and lead to differences 
in care. Sex is also usually considered in the adjustment, because some studies have reported 
gender differences namely on cardiovascular interventions: a higher mortality among women but 
fewer invasive interventions or therapeutic procedures.   
Other variables may be a part of the adjustment model namely variables that predict acute 
clinical stability, translation of immediate risk of death [20]. APACHE – Acute Physiology and 
Chronic Health Evaluation and its variations is one, among other systems that produces a score to 
predict outcome of critical illness or injury [21], uses a small number of variables like: arterial 
oxygenation and respiratory rate. 
Principal diagnose as well as the extent and severity of the co-morbidities, defined as the 
diseases that coexist to the condition of study [21],  are important risk adjustors, patients with other 
coexistent diseases are at higher risk of a negative outcome. Instead of using every disease 
separately in the adjustment it can be used one of the many co-morbidity index [22], such as 
Charlson Index [23], that produces a score that reflects the likelihood of mortality and accounts for 
conditions like dementia, diabetes and myocardial infarction. 
Building a risk-adjustment method from the scratch is demanding and very consuming, both 
time and financially, so the recommendation is to use one of the already developed and validated, 
as is or change it to fit the goals. The constrains of using a method that does not fit the purposes of 
the project completely, such as an extra caution in the results interpretation, are compensated with 
timely results [24]. In both cases it is necessary to combine clinical judgment (using published 
literature or with the help of experts) with the empirical modelling [24]; involving clinicians in the 
development brings clinical credibility to the statistical methods.  
 
Clinical indicators in hip fracture treatment 
In order to fulfil their objectives clinical indicators should measure areas that contribute with 
high mortality and morbidity, with heavy costs in care and that have potential for improvement [8, 
16]; Hip fracture is a clinical area that presents all these characteristics for that reason many 
indicator projects have specific indicators for hip fractures. 
Individual outcomes may be assessed in many ways for orthopaedic interventions on the hip, 
both generic, such as quality-of-life measures (SF-36 score, SF-12, EuroQol questionnaire,...),  as 
well as hip-specific such as Harris hip scores ( a score ranging a possible of 100, indicating the best 
possible outcome and assessing pain, function any other areas) or the Oxford hip score (measuring 
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pain and functional and ranging from 12 to 60 points, a higher score translating a greater disability) 
[25]. These measures may be helpful in the achievement of the standards defined to the indicators. 
In Portugal, the entity responsible to regulate Health (ERS – Entidade Reguladora da Saúde) 
built a system that aims to assess, objectively and consistently, the quality of care. This project, 
named SINAS [26] (Sistema Nacional de Avaliação em Saúde, National System of Health 
Assessment) is developed in cooperation with Siemens and the Joint Commission International 
(JCI- whose focus is on improving the safety of patient care [27]), as the indicators were developed 
by JCI. For orthopaedic area SINAS establishes 7 indicators: 
 Prophylactic antibiotic administration within one hour prior to surgery to patients  
submitted to total hip arthroplasty  (THA) or total knee arthroplasty (TKA); 
 Selection of prophylactic antibiotic recommended for specific surgical procedure for 
THA or TKA; 
 Discontinued prophylactic antibiotics within 24 hours after surgery end time for 
THA or TKA patients; 
 Recommended venous thromboembolism prophylaxis for THA or TKA patients; 
 THA or TKA patients who received appropriated venous thromboembolism 
prophylaxis within 24 hours prior to anesthesia start time to 24 hours after anesthesia 
end time; 
 In-hospital mortality for patients surgical treated for hip fracture; 
 Revisions to THA or TKA within 30 days after surgery. 
This project aims to produce more and better information on the quality of the health system, 
a continual improvement of health care and empower patients [26], and applies risk adjustment 
methods. 
Internationally, several agencies have been developing indicators for quality improvement, 
many of which related to hip fracture treatment. Examples of these are: Hip fracture fatality rate by 
the AHRQ – Agency for Healthcare Research and quality, United States of America, and is defined 
as the proportion of deaths of all discharged, age >= 18 years with a principal diagnosis code for 
fracture [28]. This indicator is categorized as an Inpatient Quality Indicator and reflects quality 
inside hospitals. The agency advices risk adjustments and provides both co-variables and the 
coefficients to implement the adjustment [29]; 
The International Quality Indicator Project that establishes its mission in assisting health care 
organizations in identifying opportunities for improvement in health care [30] and presents 
indicators for surgical site infections, antibiotic prophylaxis prior procedure, perioperative 
mortality, unscheduled returns to the operating room, thromboprophylaxis for surgery in hip 
arthroplasty. 
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In Denmark the Danish National Indicator Project that aims to “secure mutual grounding and 
methods for documentation and development of quality in the Danish health care system for the 
benefit of the patients”[31] has developed and validated a complete set of indicators for hip 
fractures. Six process indicators: 
 Proportion of patients who receive systematic pain assessment at rest and during 
mobilization using a pain scale; 
 Proportion of patients who are mobilized within 24 hours of the operation; 
 Proportion of patients whose basis mobility is assessed prior to discharge; 
 Proportion of patients where a rehabilitation plan is produced including ADL 
(Activities of Daily Life) functional level prior to the fracture and an ADL functional 
level prior to the discharge; 
 Proportion of patients where decision has been made regarding medical treatment to 
prevent future osteoporotic fractures; 
 Proportion of patients where decision has been made regarding future fall 
prevention; 
For these indicators the limits in standard of care are above 80% for all and above 90% for 
the majority. Another seven are available for outcome measurements, for the mortality indicator the 
project advises an adjustment. 
 Proportion of patients who survived at 30 days after admission (standard >= 90%); 
 Proportion of patients with an osteosynthesised undislocated medial fracture who are 
reoperated within 2 years (standard <= 15%); 
 Proportion of patients with an osteosynthesised dislocated medial fracture who are 
reoperated within 2 years (standard <= 30%); 
 Proportion of patients with an osteosynthesised subtrochanteric or trochanteric 
fracture who are reoperated within 2 years (standard <= 5%); 
 Proportion of patients with a hemi- or total alloplasty who are reoperated within 2 
years (standard <= 10%); 
 Proportion of patients who are reoperated due to deep wound infection within 2 
years (standard <=2%). 
The Canadian Institute for Health Information developed three indicators related to 
accessibility to surgery and a model to adjust for risk. The indicators differ in the time period 
between admission and surgery [32]: 
 Proportion of patients age 65 and older with surgery within 48 hours of admission to 
hospital; 
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 Proportion of patients age 65 and older with surgery on the day of admission or the 
next day; 
 Proportion of patients age 65 and older with surgery on the day of admission, the 
next day or the day after; 
The literature on hip fracture risk and management is used to develop and adjust indicators 
regarding delay of surgery, nutrition, delirium, patient characteristics, the intervention of 
interdisciplinary teams or hospital volume [33-39]. As quality is multidimensional any assessment 
should considered the various aspects involved in the treatment of hip fractures. 
 
Conclusion 
The use of indicators has proven to be effective in other areas, in health care the evidence is 
relatively scarce, perhaps due to considerable variation in the methods used [40]. On a systematic 
review [40] conducted in Medline and the Cochrane library, for papers published from January 
1994 to January 2008, with the search expression of “quality indi*” followed by ”hospital care” or 
“quality improvement” only 21 were included and only one mention the hip/knee as the clinical 
area to measure [41]. However, hospital measurement needs to be assessed and clinical indicators 
are the most viable tools for that. 
The importance of the indicators concerning hip fractures in hospital performance was 
recognised, in 2003, when the World Health Organization, launch a project PATH – Performance 
Assessment Tool for Quality Improvement in Hospitals [42], that developed a set of indicators 
where 3 concern hip fracture (mortality; readmission, length of stay) [43]. 
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Abstract 
The aim is to examine the temporal trends of hip fracture incidence in Portugal by sex and 
age groups, and explore the relation with anti-osteoporotic medication. 
From the National Hospital Discharge Database, we selected from 1
st
 January 2000 to 31
st
 
December 2008, 77,083 hospital admissions (77.4% women) caused by osteoporotic hip fractures 
(low energy, patients over 49 years-age), with diagnosis codes 820.x of ICD 9-CM. The 2001 
Portuguese population was used as standard to calculate direct age-standardized incidence rates 
(ASIR) (100,000 inhabitants). Generalized additive and linear models were used to evaluate and 
quantify temporal trends of age specific rates (AR), by sex. 
We identified 2003 as a turning point in the trend of ASIR of hip fractures in women. After 
2003, the ASIR in women decreased on average by 10.3 cases/100,000 inhabitants, 95% CI (-15.7 
to -4.8), per 100,000 anti-osteoporotic medication packages sold. For women aged 65-69 and 75-79 
we identified the same turning point. However, for women aged over 80, the year 2004 marked a 
change in the trend, from an increase to a decrease. Among the population aged 70-74 a linear 
decrease of incidence rate (95% CI) was observed in both sexes, higher for women: -28.0% (-36.2 
to -19.5) change vs -18.8%, (-32.6 to -2.3).. 
The abrupt turning point in the trend of ASIR of hip fractures in women is compatible with 
an intervention, such as a medication. The trends were different according to gender and age group, 
but compatible with the pattern of bisphosphonates sales. 
 
Keywords 
 
Bisphosphonates; osteoporosis; hip fractures; anti-osteoporotic medication population studies 
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Introduction 
Identifying and understanding trends of hip fracture incidence is important, not only as a way 
for planning future medical resources and treating patients but also in planning effective preventive 
measures [1]. Costs related to hip fractures are not only restricted to hospitalization but also to the 
long recovery time and assistance that these patients require [2, 3]. Public health interventions can 
be taken using knowledge gathered from epidemiologic studies using secondary data. These studies 
can provide valuable information with the use of reliable data on a national  basis [4, 5]. 
The bone quality impairment is associated to aging and elevates the risk of osteoporotic 
fractures, particularly in post-menopausal women. Furthermore, an excessive pathologic decrease 
in bone strength can be prevented either by the use of medicaments or by changing activity and 
nutritional behaviour [6]. Osteoporotic hip fractures are more common among women over the age 
of 49 years and grows exponentially with aging. With the increase of life expectancy the range of 
population at risk is considerable, enhancing the need to analyze trends by age groups. In 2008, life 
expectancy at age 65 in the European Union (27 member states) was 17.2 and 20.7 years for males 
and females respectively [7]. In Portugal, the same indicator with data from 2009-2011 was 16.9 
and 20.2 respectively (last available data) [7, 8]. Moreover, the elderly form the fastest growing age 
group in most western countries thus aggravating the burden of osteoporosis. 
In Portugal there are no national studies addressing the trend of hip fractures. However, 
internationally several studies have been conducted reporting trends of age-standardized incidence 
rates of hip fractures [1]. Nevertheless the results are not consensual: increasing, decreasing and 
stable trends have been reported, which may reflect different stages in the epidemic curve. The 
results regarding the shape of the trends as well an existing pattern in men have also differ. Studies 
in Finland [9] and Australia [10, 11] have reported rates of hip fractures compatible with a non-
linear trend. However in Finland the decrease pattern was observed in both genders, whereas in 
Australia only women presented a decreasing pattern. Rates presenting linear decreases have been 
reported by studies in Belgium [12], Denmark [13], Canada [14], United States [15] for both 
genders and Spain just for women[16]. Unique causes are impossible to assess, nevertheless studies 
have pointed out different plausible reasons, according to their results, namely medication for 
osteoporosis [10, 11, 16] or other interventions [13, 14]. 
It is important to explore time trends of age-standardized incidence rates of hip fractures 
although they may hide different underlying trends by age groups thus leading to incorrect 
conclusions. And since hip fractures affect a wide range of ages, these studies may help uncover 
unequal patterns and meaningful associations with the preventive procedures undertaken by 
different countries. 
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The aim of this work is to examine the temporal trends of hip fracture incidence in Portugal 
by sex and age group, and explore its relation with anti-osteoporotic medication. 
 
Materials and Methods 
Study Area 
 
The study area was Continental Portugal with a population of 10,135,309 inhabitants in 
2008. In 2000 there were 3,298,922 inhabitants aged 50 years or over, increasing by 11.9% in 2008 
(n= 3,691,104) [8], in contrast with a decrease of -0,6% in the population aged under 50 in the 
same period. 
 
Data 
 
Population data was the annual official estimates, per sex and 5-year age groups, except for 
2001, which was a census year. 
We used data from the National Hospital Discharge Register (NHDR). The use of this 
administrative database is mandatory since 1997 in all Portuguese public hospitals, and compiles 
information on all discharges such as gender, age, admission and discharge date; first cause of 
admission (and up to 19 secondary causes) coded according to the International Classification of 
Diseases, version 9, Clinical Modification (ICD9-CM); main diagnosis (and up to 19 secondary 
diagnoses), also coded according to the ICD9-CM; clinical interventions (up to 20); surgical 
interventions; hospital providing the care; outcome (deceased, discharge to home, discharge to 
another hospital); length of stay (LOS) and patient’s place of residence.  
In Portugal, access to the national health-care system is free and universal and due to the 
high costs involved, hip fractures are primarily treated in public hospitals. Therefore hip fractures 
are highly documented and the NHDR records the total number of admissions with a diagnosis of 
hip fracture nationwide. 
The quality of the NHDR is accessed regularly by both internal (hospitals) and external 
(ACSS – Central Administration of the National System) auditors [17].  
We selected all discharges from 1
st
 January 2000 to 31
st
 December 2008 of individuals aged 
50 years or over, with a diagnosis of hip fracture (codes ICD9-CM 820.x) caused by a low or 
moderate trauma. We excluded cases of bone cancer, readmissions for orthopedic after-care or 
complications in surgical and medical care (codes ICD9-CM: 170.x, 171.x, V54.x, 996.4), the 
exclusion expression was applied to all 20 fields containing diagnosis, and represented 0.8% of the 
cases. To account for misclassification on the diagnosis field other actions were taken, namely 
revisions were excluded based on procedures codes (81.53 Revision of hip replacement, not 
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otherwise specified) representing a total of 0.08% of the cases. In addition we also excluded cases 
with length of stay inferior to 5 days, that did not went to a surgery and that were transferred to 
another hospital, because the first hospitalization could be just to stabilize the patient, these 
represent 1.1% of the cases.  
In Portugal it is not possible to have databases linkage between NHDR and prescriptions so 
the data on medication was only available for the entire population, and therefore it was not 
possible to access sales desegregated by sex and age groups, or have the number of patients treated. 
Data was provided by the National Authority of Medicines and Health Products (INFARMED). We 
analyzed, on a national level, the number of anti-osteoporotic medication packages sold from 2000 
to 2008 through prescriptions made in the National Health System (NHS). We used the total 
number of anti-osteoporotic medication for the entire population to explain the trend of hip 
fractures in women, based on our preliminary results that showed no increasing or decreasing 
trends in ASIR for men. The stable incidence rates of hip fractures among men is compatible with 
the low prescription of anti-osteoporotic medication for men identified in other countries [12] and 
information contained in Portuguese national guidelines [18, 19] which focus the prevention of 
osteoporosis in women. The medications analyzed were those indicated as agents that can act on 
the inhibition of bone loss or promote directly bone formation [20, 21] with a high evidence level 
of reducing the risk of a hip fracture: bisphosphonates, calcitonin, hormonal replacement therapy 
(HRT), Strontium ranelate and Selective Estrogen Receptor Modulators (Reloxifene) as well as 
vitamin D (recommended to be prescribed in association with the medications mentioned [19]).  
We used the Portuguese population from the 2001 census, available from Statistics Portugal 
(Instituto Nacional de Estatística – INE) as the standard for calculating the direct age-standardized 
incidence rates (ASIR) per 100,000 inhabitants by gender. 
We calculated age-specific rates (AR) by gender, using population counts in the census year 
of 2001 and official estimates for all the other years. Five-year age groups were used from 50 to 84 
years of age and a wider group comprising all patients older than 84. 
In addition, we calculated the 95% Confidence Intervals (95% CI) for each rate according to 
the methods described in Morris and Gardner (2000) [22]. 
 
Statistical Analysis 
 
We used Generalized Additive Models (GAMs) to investigate changes in the trends of 
incidence rates. These models are flexible as they incorporate a non-parametric component that is 
implemented using spline functions (smoothers) and can reveal possible non-linearities in the effect 
of the predictors [23]; for this study we were interested in the possible non-linear effect of time in 
the incidence rates. The GAMs were used in an exploratory manner [24] to identify visually the 
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relationship of time to the mean incidence rate. For the cases where the smooth function of time 
was statistically significant, we fitted Generalized Linear Models (GLMs) to quantify formally 
changes in trends. For some models, the smooth non-parametric function was linear so we fitted a 
GLM with a linear relationship in time. In cases where the smooth function exhibited a turning 
point, we used piecewise regression with the identified turning points as the cut points, similar to 
what is described in chapter 12 of Faraway, 2006[24]. 
We modeled the ASIR as a Gaussian random variable using year as an independent 
predictor. The GLM results consisted of a linear regression coefficient (the parameter of variable 
year), in this case the average increase/decrease (depending on the signal of the coefficient) in the 
rates by an increment of one year. For women, in order to evaluate how sales of anti-osteoporotic 
medication affect the ASIR, we fitted similar models using the number of packages sold as the 
independent variable. 
We also conducted the analysis on the AR by gender using a GAM followed by a GLM to 
quantify statistically significant trends. In both cases we assumed that the incidence rates for each 
age and sex group have a different Poisson distribution, therefore for each group we explored a 
separate model. Whenever necessary, a negative binomial distribution was used to account for 
overdispersion [24]. For the AR trend analysis, the natural logarithm of the number of cases was 
modeled as function of year (nonparametric for GAM) and an offset factor of log (population size 
of each year). The results of the GLM were expressed as Incidence Rate Ratios (IRR), a relative 
risk measure representing the factor by which the rate increases/decreases with an increase of a 
year: a value lower than one represents a decrease in risk between one year and the next (decrease 
trend), a value higher than one represents an increased risk (increased trend), whereas an IRR equal 
to one represents an equal risk between two consecutive years (a steady trend). The relative 
estimated percentage change for each of the periods identified as having a statistically significant 
trend was calculated by dividing the difference between estimated rates in the final and initial year 
in the period by the estimated rate in the initial year of the period ([estimated rate final year-
estimated rate initial year]/estimated rate initial year). For all measures we calculated the 95% CI.  
For the purposes of modeling the age and sex groups separately, the older age groups were 
aggregated so that the oldest group included patients over 79 years of age. This was done in order 
to avoid underdispersion. 
Statistical analysis was performed using statistical software R version 2.14.1 (Project for 
Statistical Computing), the mgcv and MASS packages for trend analysis. 
A simplistic version of the models implemented is: 
1. GAM models for ASIR rate~s(year) and rate~s(number of anti-osteoporotic 
medication packages sold) 
2. GLM model for ASIR rate~year and rate~number of anti-osteoporotic medication 
packages sold 
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3. GAM models for AR log(cases)~s(year)+log (population) 
4. GLM models for AR log(cases)~year+log (population) 
 
Results 
During the study period we identified 77,083 hip fractures, 77.4% in women (mean age 
(standard deviation (SD)) at admission 81.0 (SD 8.5) years old versus 78.0 (SD 10.1) and (p-value 
< 0.0001) for women and men respectively. Table 1 shows number of admissions and mean age at 
admission, according to the year of admission whereas table 2 shows the ASIR and age-specific 
rates during the period of study.  
 
Table 1 – Summary of statistics of In-patients Characteristics in Portugal (2000-2008). 
Variable 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Men          
No. of 
admissions 
1752 1947 1780 1989 1981 1961 2069 1913 2027 
Age (Mean; 
(SD)) 
77.6 
(10.02) 
77.4 
(10.03) 
78.0 
(9.92) 
77.6 
(9.94) 
78.4 
(10.26) 
78.1 
(10.20) 
78.4 
(9.99) 
78.2 
(10.29) 
78.5 
(10.14) 
Women          
No. of 
admissions 
6086 6537 6295 6814 6820 6820 6892 6569 6831 
Age (Mean; 
(SD)) 
80.3 
(8.59) 
80.5 
(8.64) 
80.9 
(8.61) 
80.7 
(8.72) 
81.3 
(8.49) 
81.2 
(8.46) 
81.2 
(8.47) 
81.5 
(8.30) 
81.8 
(8.41) 
 
 
Table 2 – Age-standardized Incidence Rates (ASIR) and Age-specific Rates (AR) of Hip 
Fracture per 100,000 inhabitants (95%CI) in Portugal (2000-2008). 
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Age group 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Men          
ASIR 
119.8 (114.2 
to 125.4) 
130.0 (124.2 
to 135.7) 
116.4 (111.0 
to 121.8) 
127.8 (122.2 
to 133.5) 
123.9 (118.4 
to 129.4) 
119.2 (114.0 
to 124.53) 
121.9 (116.6 
to 127.2) 
110.0 (105.1 
to 114.94) 
113.4 (108.4 
to 118.3) 
50 - 54 14.9 (10.8 to 
20.0) 
17.4 (13.1 to 
22.8) 
14.5 (10.6 to 
19.4) 
20.0 (15.3 to 
25.6) 
16.9 (12.7 to 
22.1) 
15.2 (11.2 to 
20.1) 
12.9 (9.3 to 
17.5) 
14.9 (11.0 to 
19.8) 
19.3 (14.8 to 
24.6) 
55 – 59 26.1 (20.2 to 
33.1) 
25.1 (19.4 to 
31.9) 
19.6 (14.7 to 
25.7) 
26.5 (20.8 to 
33.3) 
25.5 (20.0 to 
32.0) 
27.4 (21.8 to 
34.1) 
30.8 (24.8 to 
37.7) 
28.0 (22.3 to 
34.6) 
23.2 (14.8 to 
29.3) 
60 – 64 32.2 (25.5 to 
40.2) 
40.2 (32.6 to 
49.1) 
36.1 (28.9 to 
44.5) 
34.3 (27.3 to 
42.5) 
39.3 (31.8 to 
48.0) 
35.0 28.1 to 
43.1) 
32.1 (25.5 to 
39.8) 
36.5 (29.6 to 
44.7) 
35.5 (28.7 to 
43.4) 
65 -69 70.3 (59.9 to 
81.9) 
82.9 (71.6 to 
95.4) 
68.0 (57.9 to 
79.5) 
65.5 (55.6 to 
76.7) 
61.3 (51.7 to 
72.2) 
67.8 (57.7 to 
79.3) 
66.6 (56.4 to 
78.1) 
67.7 (57.5 to 
79.3) 
55.9 (46.6 to 
66.5) 
70 -74 115.4 (100.6 
to 131.9) 
142.8 (126.4 
to 160.8) 
113.5 (99.2 
to 129.4) 
140.6 (124.7 
to 158.0) 
112.3 (98.2 
to 127.9) 
115.4 (101.2 
to 131.0) 
119.2 (104.8 
to 135.0) 
101.0 (87.8 
to 115.6) 
105.1 (91.7 
to 119.9) 
75 - 79 265.4 (238.8 
to 294.1) 
259.0 (233.1 
to 287.1) 
236.4 (211.8 
to 263.1) 
266.2 (240.3 
to 294.2) 
239.5 (215.1 
to 266.0) 
226.9 (203.5 
to 252.4) 
256.7 (232.0 
to 283.3) 
198.0 (176.8 
to 221.1) 
237.8 (214.8 
to 262.7) 
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80 - 84 
467.8 (419.3 
to 520.4) 
502.5 (453.8 
to 555.1) 
474.3 (428.0 
to 524.2) 
494.0 (448.0 
to 543.4) 
480.8 (436.7 
to 528.3) 
479.6 (436.0 
to 526.4) 
489.9 (446.4 
to 536.5) 
465.1 (423.2 
to 510.0) 
436.0 (396.0 
to 479.0) 
>84 
1042.3 
(951.0 to 
1140.1) 
1101.5 
(1008.2 to 
1201.3) 
1048.1 
(957.6 to 
1145.0) 
1129.2 
(1034.7 to 
1230.0) 
1241.3 
(1144.1 to 
1344.7) 
1108.9 
(1019.4 to 
1204.3) 
1089.0 
(1003.0 to 
1180.4) 
972.4 
(893.0 to 
1057.0) 
1055.7 
(974.8 to 
1141.5) 
Women          
ASIR 
336.2 (327.8 
to 344.7) 
352.9 (344.4 
to 361.5) 
333.7 (325.4 
to 341.9) 
356.0 (347.5 
to 364.5) 
346.5 (338.3 
to 354.7) 
336.2 (328.3 
to 344.2) 
329.4 (321.6 
to 337.2) 
305.3 (297.9 
to 312.7) 
308.8 (301.5 
to 316.2) 
50 - 54 14.8 (10.9 to 
19.7) 
14.5 (10.6 to 
19.2) 
15.4 (11.4 to 
20.2) 
18.7 (14.3 to 
24.0) 
11.7 (8.3 to 
15.9) 
16.0 (12.0 to 
20.8) 
13.0 (9.4 to 
17.4) 
12.6 (9.1 to 
16.9) 
13.3 (9.7 to 
17.7) 
55 – 59 30.9 (24.8 to 
38.0) 
31.4 (25.4 to 
38.5) 
24.8 (19.5 to 
31.1) 
33.4 (27.3 to 
40.4) 
24.7 (19.5 to 
30.8) 
29.2 (23.5 to 
35.7) 
25.2 (20.1 to 
31.3) 
19.1 (14.7 to 
24.4) 
24.9 (19.8 to 
31.0) 
60 - 64 54.5 (46.2 to 
63.8) 
61.7 (52.7 to 
71.7) 
54.6 (46.2 to 
64.0) 
59.5 (50.7 to 
69.3) 
54.7 (46.4 to 
64.1) 
49.3 (41.5 to 
58.1) 
58.8 (50.4 to 
68.2) 
52.1 (44.2 to 
60.9) 
49.1 (41.6 to 
57.6) 
65 - 69 122.3 (109.7 
to 136.0) 
122.8 (110.2 
to 136.4) 
124.8 (112.1 
to 138.6) 
133.8 (120.6 
to 148.0) 
118.1 (105.7 
to 131.5) 
114.5 (102.2 
to 127.8) 
113.9 (101.5 
to 127.4) 
102.7 (90.9 
to 115.6) 
90.5 (79.4 to 
102.6) 
70 -74 319.9 (297.9 
to 343.1) 
333.3 (311.0 
to 356.8) 
259.4 (239.9 
to 280.0) 
286.3 (266.0 
to 307.8) 
277.1 (257.3 
to 298.1) 
248.5 (229.9 
to 268.3) 
263.2 (244.0 
to 283.4) 
232.5 (214.5 
to 214.1) 
232.1 (214.1 
to 251.1) 
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75 – 79 622.0 (587.5 
to 658.0) 
636.5 (602.1 
to 672.4) 
603.8 (570.6 
to 638.4) 
637.2 (603.5 
to 672.4) 
600.8 (568.2 
to 634.7) 
589.0 (557.1 
to 622.3) 
584.8 (553.3 
to 617.7) 
529.1 (499.5 
to 560.0) 
541.5 (511.9 
to 572.5) 
80 – 84 
1122.4 
(1063.2 to 
1184.0) 
1154.4 
(1095.7 to 
1215.3) 
1086.2 
(1030.7 to 
1143.9) 
1154.7 
(1099.1 to 
1212.3) 
1162.6 
(1108.2 to 
1219.0) 
1174.2 
(1120.2 to 
1230.1) 
1108.8 
(1057.4 to 
1162.0) 
1055.4 
(1006.0 to 
1106.7) 
1003.8 
(956.2 to 
1053.1) 
>84 
2138.3 
(2048.1 to 
2231.4) 
2323.0 
(2229.5 to 
2419.5) 
2332.1 
(2238.5 to 
2428.6) 
2450.0 
(2353.3 to 
2549.7) 
2465.8 
(2370.3 to 
2564.3) 
2353.0 
(2261.8 to 
2446.9) 
2277.8 
(2190.3 to 
2368.0) 
2157.5 
(2073.9 to 
2243.6) 
2285.3 
(2201.1 to 
2371.0) 
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The age groups where the smooth function of time was statistically significant, indicating a 
statistically significant trend of incidence rates according to time, were 55-59, 65-69, 70-74, 75-79 
and over 79 years-old and over in women and 70-74 years-old in men. The following figures 1 and 
2 show the statistically significant smooth functions of time by age groups in both sexes and in 
table 3 we present the results for the age-specific rates using the quantification given by the GLM 
models.  
 
We identified a linear effect of time in the age groups 55-59 for women and 70-74 for both 
genders (figures 1 and 2). For the other age groups in women, we identified a point within the 
period which determines a turn in the trend; these turning points are either increasing to decreasing 
or an alteration in the velocity of decrease. For women aged 65-69 and 75-79 years, 2003 can be 
visually identified from figure 1 as the year where a change occurred. For older women aged more 
than 79, we identified 2004 as the turning point in the trend. 
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Figure 1 Smooth function of time in AR for women aged: 55-59 years-old (panel A), 65-69 
years-old (panel B), 75-79 years-old (panel C) and over 79 years-old (panel D). 
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Figure 2 Smooth function of time in AR for women aged 70-74 years-old (panel A) and for men 
aged 70-74 (panel B) 
 
In figure 3 it can be observed the evolution of anti-osteoporotic medication sales during the 
period of study. It can clearly be observed that after 2003 the number of biphosphonates packages 
is the major responsible for the total amount of anti-osteoporotic packages sold. 
 
 
Figure 3 Sales of medication for the prevention of osteoporosis and reduction of fracture 
risk in Portugal 
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Analysis of the ASIR by gender revealed a statistically significant effect of time only among 
women (Figure 4, panel A). This effect is non-linear and the year 2003 was identified as the turning 
point in the trend. 
 
Figure 4 Smooth function of time in Age-standardized Incidence Rates (ASIR) for women 
(panel A) and of total number of packages for anti-osteoporotic sold in Age-standardized Incidence 
Rates (ASIR) for women (panel B). 
 
The linear model for the ASIR in women for the period 2000-2003 revealed that for each 
year, the incidence rate increased on average by 5.1 cases per 100,000 inhabitants with a 95% CI (-
1.6 to 11.7). As for the period 2003-2008, the decrease trend was statistically significant with an 
average decrease of 9.6 cases per 100,000 inhabitants with a 95% CI (-13.4 to -5.7).  
 
The non-linear effect of total number of anti-osteoporotic packages sold in ASIR (figure 4 
panel B) is identical to that of time in ASIR (figure 4 panel A) with the same turning point 
identified in 2003. From 2003 the decrease of 10.2 cases per 100,000 inhabitants with 100,000 
packages sold was statistically significant: 95% CI (-15.7 to –4.8). 
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Table 3 – Incidence Rate Ratios (IRR), Percentage relative change and corresponding 95% 
CI calculated with GLM 
 
Age-gender group IRR (95% CI) % Change (95% CI) 
Men Period Period 
70 -74 2000-2008 2000-2008 
0.974 (0.952 to 0.997) -18.81 (-32.56 to -2.25) 
Women Period Period 
55 - 59 2000-2008 2000-2008 
0.961 (0.932 to 0.991) -27.36 (-43.18 to -7.18) 
65 - 69 2000-2003 2003-2008 2000-2003 2003-2008 
1.027 (0.986 to 
1.070) 
0.937 (0.914 to 
0.961) 
8.28 (-4.23 to 22.52) -27.63 (-36.21 
to -17.94) 
70 -74 2000-2008 2000-2008 
0.959 (0.945 to 0.973) -28.36 (-36.24 to -19.52) 
75 - 79 2000-2003 2003-2008 2000-2003 2003-2008 
1.00 (0.980 to 
1.020) 
0.968 (0.957 to 
0.981) 
-0.48 (-5.78 to 7.17) -14.79 (-19.89 
to -9.38) 
>79 
2000-2004 2004-2008 2000-2004 2004-2008 
1.013 (1.005 to 
1.023) 
0.972 (0.963 to 
0.980) 
5.71 (1.98 to 9.58) -10.86 (-13.87 
to -7.76) 
 
 
Discussion 
In this population-based retrospective study, the year 2003 appeared as a turning point in the 
time trend of age-standardized incidence rate (ASIR) of hip fracture in women. The observed trend 
from 2000-2008 with a clear and abrupt decrease change in 2003, is compatible with an 
intervention on national level. When analysing by sex, the anti-osteoporotic medication packages 
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sold, in each of the years within the study period, had the same impact on the trend of ASIR for 
women, with the same turning point relating to 2003 sales.  
After 2003, with the decrease of HRT, the total number of anti-osteoporotic packages are 
manly bisphosphonates, suggesting that the massive increase in prescription of these medications 
was the intervention responsible for the change in the trends of ASIR. The rapidly increase of 
bisphosphonates sales can be the result of Bone and Joint Decade actions, that raised awareness to 
prevention, translating in a higher amount of individuals protected and consequently a decrease of 
incidence rates. However, in Portugal the number of patients treated cannot be assessed, as it is not 
possible to linkage different health related databases. Furthermore, the results by gender and age 
group are compatible with this hypothesis. The turning points were only present in women and the 
change was first observed in the age groups which are the target of these prescriptions in Portugal. 
Regardless of no causal relationship being able to be attributed is an ecological study, it 
acknowledges an important aspect that needs further clarification.  
The existence of a turning point can be identified visually in other studies [9-11] where the 
change was attributed to bisphosphonates [10, 11]. However, when the trend is linear and present in 
both men and women [13-15] questions the extent of bisphosphonates influence were raised [13, 
14]. Results similar to ours were observed in a study from Australia [11] and a following study 
from the same population [10] showed that a decrease in bisphosphonates sales was followed by an 
increase of hip fracture incidence, underlying the possibility of the trends of hip fracture incidence 
rates being driven by bisphosphonates.  
A change in the trend could be attributed to other factors, however it is unlikely that a 
change in the demographic and socioeconomic characteristics of the population could occur so 
promptly that impacted on hip fracture incidence so abruptly has our results pointed out. Other 
interventions, such as falls prevention campaigns, are usually focused on the elderly age groups 
(over 80 years old) and were not implemented nationwide in Portugal. Falls prevention actions in 
Portugal are sparse, conducted locally in some health centers (local impact) and they did not occur 
simultaneously, therefore it is not likely that such local actions would explain the accentuated 
turning points in the time trends of ASIR nationwide.  
Our study has limitations that in our perspective do not invalidate the results. The relation 
between the number of bisphosphonates sold and age-standardized incidence rates for women can 
be questioned because no confounders were used to adjust the effect. In our opinion, the traditional 
risk factors for osteoporotic hip fractures that could be seen as confounders, such as socioeconomic 
status or cohort effect, would not have a sudden impact on ASIR, since they do not vary abruptly in 
time. In our study, the period of 9 years would not be long enough to observe major differences in 
traditional risk factors at ecological level and even so, they would not have an abrupt impact 
capable of a turning point in the time trends at national level, we would expect a continuous linear 
trend like the one obtained on 70-74 age group for both genders.  
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The strength of our study can be attributed to the data and the statistical methods applied. 
Our data covers a wide geographic scope, with data containing both hip fractures and medication 
sales on a national level (excluding the 5% of the population that lives in the autonomous regions), 
which overmatch local studies. In this paper we analyzed data from several perspectives using 
flexible models, which to our knowledge have not been used on epidemiological studies of hip 
fractures. These methods allowed the identification of non-linear effects, complemented with 
parametric models that allowed the quantification of the decreasing patterns, after the abrupt 
change. The trends of osteoporotic hip fractures require analysis not only of the age-standardized 
incidence rates by gender (which can hide unequal patterns by age groups) but also disaggregate 
analysis by age groups, since the risk increases exponentially with age and the population at risk 
may require differentiated care.  
The incidence rates of hip fractures showed a decreasing trend with a well defined turning 
point in some age groups. Nevertheless the number of fractures is still raising and with the aging of 
the population this problem tends to be aggravated, increasing the costs of treatment and 
rehabilitation of patients. We identified trends of hip fractures at national level and these results 
may help making better decisions, it is important to have similar studies, in Portugal and other 
countries, in the following years to help understanding the role of anti-osteoporotic medication on 
hip fracture incidence, especially with the introduction of strontium ranelate that proved to have a 
positive impact on some parameters of hip structure, namely bone mineral density [25], but with 
inconclusive results regarding the decrease of hip fracture risk [26].  
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Abstract 
Purpose: 
Healthcare improvements allowed preventive hip fractures measures but also increased life 
expectancy resulting into more people at risk. The aim is to analyse the effects of age, period and 
cohort on hip fractures incidence rates by sex, in the 2000-2008 period. 
Methods: 
We used data from the National Hospital Discharge Database (2000-2008), caused by hip 
fractures (ICD 9-CM codes 820.x, low energy, patients older than 49). Person-years at risk were 
calculated using 2001 Portuguese census and official estimates. We fitted an age-period-cohort 
model (age and period intervals with one year amplitude) that allows the identification of period 
and cohort effects for all age groups, followed by Generalized Additive Models (GAM) with a 
negative binomial distribution of the observed incidence rates of hip fractures. 
Results: 
We found a statistically significant cohort effect in the 77 083 hospital admissions (77.4% 
women) analyzed. The year 1930 divides the general pattern in women: increasing until 1930, 
decreasing afterwards. Although not statistically significant, there are risk fluctuations, around 
1920 (stable to increasing), 1940 (decreasing to increasing) and 1950 (increasing to decreasing) 
coincident with political and economic changes in the History of Portugal. In men, the cohort effect 
presents inflections in the same years, except for 1950. In women the period effect was a 
decreasing trend after 2004, whereas in men the pattern was random. An exponential like effect 
was identified in both genders. 
Conclusions: 
 Bone quality reflects a lifetime of exposures; economical/political aspects affecting the 
population’s health can help understanding the observed cohort effect. 
 
Keywords 
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Introduction 
Advances in medicine and healthcare led to the development of medications for the 
prevention of hip fractures [1] but also to the increase of life expectancy; therefore, more people 
are at risk to sustain hip fractures. These fractures have a negative impact not only at individual 
level but also at societal level, leading to heavy economic burdens due to immediate treatment and 
long-term recovery [2].  
Hip fracture is a consequence of osteoporosis, a skeletal disorder characterized by 
compromised bone strength [3]. Bone, a highly metabolic tissue, is constantly in a process of 
formation/resorption. In the first decades of life the formation is superior to resorption, with roles 
reversed after the third decade of life [4]. The focus of hip fracture prevention has been in retarding 
the rate of resorption [5] and in preventing falls, the most common trigger mechanism. 
Nevertheless, there have been considerations regarding the importance of adequate intrauterine 
growth in the risk of hip fracture [5, 6]. 
The common approach to the study of age, period (date of diagnosis) and cohort (date of 
birth) effects on hip fracture incidence has failed in the understanding of the separated role of the 
time dimensions. Few studies reported the use of combined analysis to untangle the age-period-
cohort (APC) effects [7-9]. The age effect in hip fracture incidence is well described, the risk of 
fracture increases exponentially in the elderly [10]. However period and cohort effects are more 
difficult to understand separately and can bias hypothesis formulation. 
Interventions such as anti-osteoporosis medication are seen as period effects, which can 
modify the time trends of incidence rates [11-13]. Cohort effects act differently on generations and 
can result from changes in wellbeing and quality of health care throughout life [7]. To obtain a 
reliable explanation for the time trends of hip fracture incidence, the APC dimensions should be 
addressed using a unique analysis than can provide the separation of the individual effects. 
In a previous study we identified a period effect with a turning point in 2003 in the hip 
fracture incidence rates in women. Following that year an abrupt decrease was observed, 
compatible with the increased sales of anti-osteoporotic medication packages. In men no pattern 
was identified [14].  
Using a combined approach of estimating APC effects, the aim of this study is to report age, 
period and cohort effects on hip fracture incidence in Portugal by sex, using national 
hospitalization data from 2000-2008. 
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Methods 
Data 
 
Data from the National Hospital Discharge Register (NHDR) were selected. The use of this 
administrative database is mandatory for all Portuguese public hospitals since 1997, and compiles 
information on all discharges such as gender, age, admission and discharge date; cause of 
admission and main diagnosis (and up to 19 secondary causes and diagnosis) coded according to 
the International Classification of Diseases, version 9, Clinical Modification (ICD9-CM); among 
others.  
In Portugal, access to the national health-care system is universal and tendentiously free-of-
charge, taking into account citizens’ social and economic conditions [15]. 
 Due to the high costs involved, hip fractures are primarily treated in public hospitals; 
therefore the admissions registered in the NHDR represent almost the totality nationwide. The 
quality of the NHDR is accessed regularly by internal (hospitals) and external (ACSS – Central 
Administration of the National System) auditors [16].  
We selected all discharges from 1 January 2000 to the 31 December 2008 according to the 
epidemiological indicator of osteoporosis:  
- patients aged 50 years or over; 
- diagnosis of hip fracture (codes ICD9-CM 820.x); 
- caused by a low energy trauma.  
We excluded cases of bone cancer, readmissions for orthopaedic after-care or complications in 
surgical and medical care (codes ICD9-CM: 170.x, 171.x, V54.x and 996.4).  
Data were grouped by sex, period of diagnosis (by each calendar year) and age (one year 
intervals), from 50 to 99 years old. We limited the analysis to 99 years old to avoid statistical 
instability because from that age on there were few cases and small population. 
We used population data from the 2001 Census and the official estimates for the remaining 
years of the study period [17] to calculate person-years at risk, using the approach described in 
Carstensen, 2007 [18].  
Statistical analysis 
 
We calculated age-specific incidence rates per 100 000 person-years, by sex. Exploratory 
analysis, prior to statistical modelling, was done using five-year age groups (except for the older 
Chapter IV   
 
 
 
 
52 
age group), from age 50 to 94; the last age group was 95 to 98 years old (due to the algorithm for 
calculating person-years). We calculated the 95% Confidence Intervals (95% CI) for each 
incidence rate according to the methods described in Morris and Gardner (2000) [19]. 
 
The incidence rates were modelled as functions of A (age), P (period) and C (cohort), using 
an underlying negative binomial distribution, to correct for overdispersion [20]. A simplistic 
formulation for the models is: 
cases~f(A)+g(P)+h(C)+person-years 
where 
f, g and h are non-parametric smooth functions (natural splines); 
The statistical analysis was developed using the apc.fit implemented on the epi package from 
software R version 2.15.2 (The R Foundation for Statistical Computing) [21]. The drift parameter, 
which represents the linear secular trend that cannot be exclusively explained as period or as cohort 
effect, was extracted using the weighted method.  
The problem of separating the APC effects is well described in the literature and several 
methods have been proposed to overcome the identifiability problem caused by the linear 
dependency between the three variables (age-period-cohort) [22, 23]. To overcome such problem 
we used previous knowledge [14] to choose the parameterization: set the cohort function at zero at 
1920 (median of birth date for women, the same reference was used for men to allow comparisons) 
and constrain the period effects to be zero on average with zero slope. Estimates can vary with 
different parameterizations; however curvature of the effect is invariant. With this approach we 
could identify whether period had the same effect (decreasing, increasing or stable incidence rates) 
on all age-groups – the period effect, and/or if all birth cohorts had similar behaviours (decreasing, 
increasing or stable incidence rates) - the cohort effect.  
Following this exploratory analysis, an age, period, cohort analysis was also performed using 
Generalized Additive Models (GAM). These models are more robust since they allow the 
identification of non-linear effects of the predictors (age, period and cohort) in the response 
variable (incidence rate of hip fracture), through spline functions (smoothers) [24]. This approach 
was implemented using mgcv package of R, where restrictions to overcome the identifiability 
problem were implemented in GAM algorithm: constraining the smooth functions to have zero 
mean [25]. This method allows the visualization of the smoother functions in the mean incidence 
rate of hip fracture for all the effects - age, period and cohort - adjusted for the others. 
Interpretation of the resulting graphs are: increasing patterns are increasing risk regarding the mean 
incidence rate, decreasing patterns are decreasing risk regarding the mean incidence rate; if the 
confidence intervals (CI) contains the zero then the effects are not statistical significant. 
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Results 
During the study period we identified 77 083 hip fractures, 77.4% in women with a mean 
age of 81.0 years-old (standard deviation (SD) 8.5 years-old), higher than mean age of men (78.0 
years-old (SD 10.1)) (p-value < 0.0001). We excluded 208 cases in patients older than 99 years (26 
cases in men and 182 cases in women).  
Age-specific incidence rates by sex, for each of the period years are listed in table 1. In men, 
fluctuations in all age groups can be observed, whereas the incidence rates in women presented a 
more stable decreasing pattern. 
 
Table 1: Age specific crude incidence rates per 100,000 person-years and 95% confidence 
intervals, by sex, for each of the period years 2000-2008. 
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Sex Age-
groups 
Period Years 
Men 2000 2001 2002 2003 2004 2005 2006 2007 2008 
50-54 13.6 (9.8 to 
18.2) 
16.5 (12.4 to 
21.6) 
14.2 (10.3 to 
19.0) 
19.6 (15.1 to 
25.2) 
17.0 (12.7 to 
22.2) 
15.5 (11.4 to 
20.5) 
13.4 (9.6 to 
18.2) 
16.0 (11.8 to 
21.2) 
19.7 (15.1 to 
25.2) 
55-59  22.2 (17.2 to 
28.1) 
22.0 (17.0 to 
28.0) 
17.9 (13.4 to 
23.5) 
25.6 (20.1 to 
32.1) 
25.9 (20.3 to 
32.5) 
29.1 (23.1 to 
36.3) 
34.5 (27.8 to 
42.3) 
32.7 (26.1 to 
40.4) 
24.4 (19.00 
to 30.8) 
60-64  29.9 (23.7 to 
37.3) 
47.6 (30.5 to 
45.8) 
34.4 (27.5 to 
42.4) 
33.4 (26.6 to 
41.4) 
39.3 (31.8 to 
48.0) 
36.3 (29.2 to 
44.8) 
33.9 (27.0 to 
42.1) 
39.0 (31.5 to 
47.7) 
36.3 (29.5 to 
44.3) 
65-69  72.1 (61.5 to 
84.0) 
84.9 (73.4 to 
97.8) 
68.8 (58.5 to 
80.4) 
65.9 (55.9 to 
77.2) 
61.7(52.1 to 
72.6) 
67.3 (57.3 to 
78.7) 
65.0 (55.1 to 
76.2) 
66.1 (56.1 to 
77.4) 
54.2 (45.2 to 
64.5) 
70-74 104.0 (90.6 
to 118.8) 
131.8 (116.6 
to 148.3) 
108.2 (94.5 
to 123.4) 
137.5 (121.9 
to 154.5) 
113.3 (99.1 
to 129.0) 
120.4 (105.6 
to 136.7) 
127.6 (112.2 
to 144.5) 
110.4 (96.0 
to 126.4) 
108.4 (94.6 
to 123.8) 
75-79 226.1 (203.4 
to 250.5) 
231.6 (208.4 
to 256.7) 
220.8 (197.8 
to 245.7) 
259.4 (234.1 
to 286.7) 
240.5 (216.0 
to 267.1) 
237.4 (212.9 
to 264.1) 
280.7 (253.8 
to 309.8) 
228.2 (203.7 
to 254.8) 
251.3 (226.9 
to 277.6) 
80-84 346.2 (310.3 
to 385.1) 
405.3 (365.9 
to 447.7) 
410.9 (370.8 
to 454.1) 
463.9 (420.8 
to 510.3) 
492.8 (447.5 
to 541.4) 
527.4 (479.4 
to 578.9) 
583.7 (531.9 
to 639.2) 
598.5 (544.6 
to 656.3) 
492.6 (447.4 
to 541.2) 
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85-89 891.3 (795.3 
to 995.8) 
896.3 (801.6 
to 999.2) 
794.9 (707.5 
to 890.2) 
932.1 (839.2 
to 1032.6) 
889.4 (800.4 
to 985.7) 
805.8 (722.6 
to 896.1) 
783.9 (703.3 
to 871.4) 
702.5 (627.8 
to 783.6) 
870.8 (789.1 
to 958.7) 
90-94 1398.0 
(1173.7 to 
1653.0) 
1486.0 
(1259.1 to 
1742.2) 
1414.2 
(1197.6 to 
1658.9) 
1166.3 
(974.5 to 
1385.2) 
1632.9 
(1409.0 to 
1882.6) 
1457.1 
(1250.4 to 
1688.5) 
1529.8 
(1322.1 to 
1761.0) 
1397.1 
(1203.1 to 
1613.8) 
1200.6 
(1024.9 to 
1398.0) 
95-98 2072.3 
(1353.7 to 
3036.3) 
2106.8 
(1411.1 to 
3025.7) 
2382.5 
(1668.7 to 
3298.4) 
1506.2 
(974.7 to 
2223.4) 
2358.3 
(1706.7 to 
3176.7) 
1995.8 
(1425.9 to 
2717.8) 
2269.1 
(1684.2 to 
2991.6) 
1610.0 
(1148.9 to 
2200.9) 
1426.1 
(1009.2 to 
1957.4) 
Women  2000 2001 2002 2003 2004 2005 2006 2007 2008 
50-54 13.6 (10.0 to 
18.1) 
13.8 (10.1 to 
18.3) 
15.1 (11.2 to 
19.8) 
18.4 (14.1 to 
23.6) 
11.7 (8.3 to 
16.0) 
16.3 (12.3 to 
21.3) 
13.4 (9.8 to 
18.0) 
13.4 (9.7 to 
18.0) 
13.5 (9.5 to 
18.0) 
55-59  27.1 (21.7 to 
33.3) 
28.5 (23.0 to 
34.9) 
23.3 (18.3 to 
29.2) 
32.7 (26.7 to 
39.6) 
24.9 (19.7 to 
31.1) 
30.3 (24.5 to 
37.1) 
27.4 (21.8 to 
34.0) 
21.6 (16.6 to 
27.6) 
25.9 (20.6 to 
32.1) 
60-64  50.5 (42.8 to 
59.1) 
57.2 (48.9 to 
66.5) 
51.6 (43.7 to 
60.5) 
57.7 (49.2 to 
67.2) 
54.8 (46.5 to 
64.3) 
51.4 (43.3 to 
60.6) 
62.6 (53.6 to 
72.7) 
55.9 (47.5 to 
65.4) 
50.4 (42.7 to 
59.1) 
65-69  127.0 (113.9 
to 141.2) 
127.6 (114.5 
to 141.8) 
127.8 (114.8 
to 142.0) 
135.4 (122.1 
to 149.8) 
118.5 (106.1 
to 132.0) 
112.5 (100.5 
to 125.6) 
109.8 (97.9 
to 122.8) 
98.7 (87.4 to 
111.1) 
86.7 (76.1 to 
98.3) 
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70-74 295.2 (274.9 
to 316.6)  
311.2 (290.4 
to 333.2) 
248.9 (230.2 
to 268.6) 
280.7 (260.8 
to 301.8) 
279.3 (259.3 
to 300.4) 
257.7 (238.4 
to 278.2) 
279.2 (258.9 
to 300.7)  
250.2 (230.8 
to 270.7) 
236.4 (218.1 
to 255.8)  
75-79 532.9 (503.3 
to 536.7) 
574.1 (543.1 
to 606.4) 
567.8 (536.6 
to 600.3) 
622.6 (589.6 
to 656.9) 
605.3 (572.5 
to 639.5) 
615.5 (582.2 
to 650.3) 
634.8 (600.6 
to 670.4) 
604.1(570.3 
to 639.4) 
567.8 (536.7 
to 600.2) 
80-84 823.5 (780.1 
to 868.8) 
914.2 (867.8 
to 962.5) 
932.5 (884.9 
to 982.1) 
1085.6 
(1033.4 to 
1139.8) 
1189.2 
(1133.5 to 
1246.9) 
1294.8 
(1235.2 to 
1356.4) 
1340.0 
(1277.9 to 
1404.4) 
1380.4 
(1315.7 to 
1447.4) 
1133.3 
(1079.6 to 
1188.9) 
85-89 1871.7 
(1771.4 to 
1976.3) 
1983.6 
(1882.1 to 
2089.2) 
1900.5 
(1802.9 to 
2002.1) 
1853.7 
(1759.1 to 
1952.1) 
1687.4 
(1599.0 to 
1779.5) 
1721.2 
(1633.6 to 
1812. 7) 
1683.8 
(1598.3 to 
1772.8) 
1642.4 
(1559.6 to 
1728.4) 
1747.9 
(1664.1 to 
1834.7) 
90-94 2728.5 
(2525.2 to 
2943.9) 
2740.5 
(2540.7 to 
2952.0) 
2736.0 
(2540.2 to 
2943.0) 
2804.0 
(2609.6 to 
3009.2) 
3198.1 
(2994.2 to 
3412.3) 
2929.0 
(2737.8 to 
3130.1) 
2724.4 
(2543.7 to 
2914.7) 
2506.4 
(2336.6 to 
2685.4) 
2524.7 
(2357.5 to 
2700.7) 
95-98 2750.5 
(2284.1 to 
3284.8) 
3481.9 
(2972.4 to 
4054.3) 
3063.3 
(2602.9 to 
3582.3) 
3139.8 
(2689.4 to 
3644.7) 
3325.6 
(2877.4 to 
3824.2) 
2700.0 
(2311.6 to 
3135.5) 
3166.8 
(2759.5 to 
3617.7) 
2618.3 
(2261.9 to 
3015.2) 
3076.6 
(2702.7 to 
3488.2) 
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The analysis of the deviance between adjacent lines (table 2, a lower p-value indicates a 
more suitable model than the previous) indicates that a full APC model is more adequate for 
women (identifications of both period and cohort effects are statistically significant), whereas in 
men the trends seem to be explained more accurately using the age-period model. 
 
Table 2 - Comparison between simpler models for men and women, through the comparison of 
adjacent lines and the p-value from F-test. 
 Men Women 
Model Residual 
Deviance 
(DF- Degrees 
of Freedom) 
Deviance 
difference 
(DF 
difference)  
p-value Residual 
Deviance 
(DF) 
Deviance 
difference 
(DF 
difference)  
p-value 
Age 687.6 (437)   1385.2 (437)  - 
Age+drift 675.2 (436) 12.4 (1) 0.0004 1374.8(436) 10.4 (1) 0.001 
Age+Cohort 673.2 (434) 2.0 (2) 0.3422 1313.0 (434) 61.8 (2) 3.6×10
-4 
Age+Cohort+Period 653.8 (432) 19.4 (2) 6.6×10
-5 
1237.6 (432) 75.435 (2) <2.2×10
-
16 
Age+Period 656.6 (436) -2.7 (2) 0.25439 1299.5 (434) -61.9 (2) 3.6×10
-14 
Age+Drift 675.2(436) -18.7 (2) 8.8×10
-5 
1374.8 (436) -74.3 (2) <2.2×10
-
16 
 
Figure 1 represents the estimate effect from APC models, using the apc.fit for women and 
men. Similar age effects for both genders can be observed, plus a similar cohort effect until around 
1938/39. 
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Figure 1: Estimated effects for hip fracture incidence rate using the Age-Period-Cohort 
model. For each sex (women in black, men light grey) three curves are displayed and can be 
interpreted as: The left curves are the age-specific incidence rates for 100 000 person-years. The 
centre curves are the rate ratios relative to the 1920 cohort. The curve on the right side shows 
residuals ratio rates relative to period effect. Fitted values are plotted with 95% confidence 
intervals. 
 
Table 3 displays the rate ratios relative to cohort 1920 plotted on the centre graph of figure 1, 
for both men and women. For the parameterization used, the rate ratio (RR) varies from an 
estimated decrease risk of 57% in the 1958 birth cohort to an increased risk of 19% in 1934, 1935 
and 1936 birth cohorts in women. In men, the estimated RR varies from a decreased risk of 5% in 
1904-1910 (although not statistically significant) to an increased risk of 42% in 1956 birth cohorts.  
 
Table 3: Rate ratios of birth cohort and 95% CI relative to 1920, for men and women. 
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Cohort 
Men  Women  
Cohort 
Men  Women  
Cohort 
Men  Women 
RR (95% CI) RR (95% CI) RR (95% CI) 
1902 0.96 (0.77 to 1.19) 
1.02 
 (0.91 to 1.13) 1920 Reference Reference 1938 
1.3  
(1.13 to 1.49) 
1.16 
 (1.08 to 1.26) 
1903 
0.96 
(0.78 to 1.17) 
1.01  
(0.92 to 1.11) 1921 
1.01 
 (1 to 1.02) 1.01 (1.01 to 1.01) 1939 
1.31  
(1.14 to 1.51) 
1.14 
 (1.05 to 1.24) 
1904 
0.95 
(0.79 to 1.15) 
1  
(0.92 to 1.1) 1922 
1.02 
 (1.01 to 1.03) 
1.02 
 (1.01 to 1.03) 1940 
1.33  
(1.14 to 1.54) 
1.12  
(1.02 to 1.22) 
1905 
0.95  
(0.8 to 1.13) 
1  
(0.92 to 1.09) 1923 
1.03 
 (1.01 to 1.05) 
1.04 
 (1.02 to 1.05) 1941 
1.34 
 (1.15 to 1.56) 
1.09 
 (0.99 to 1.19) 
1906 
0.95 
(0.81 to 1.12) 
0.99  
(0.92 to 1.07) 1924 
1.05  
(1.02 to 1.08) 
1.05  
(1.04 to 1.07) 1942 
1.35  
(1.15 to 1.59) 
1.05 
 (0.95 to 1.16) 
1907 
0.95 
(0.83 to 1.1) 
0.99  
(0.92 to 1.06) 1925 
1.06 
 (1.03 to 1.1) 
1.07  
(1.05 to 1.09) 1943 
1.36  
(1.15 to 1.61) 
1.02  
(0.91 to 1.13) 
1908 
0.95  
(0.84 to 1.09) 
0.98  
(0.93 to 1.05) 1926 
1.08  
(1.03 to 1.12) 
1.08 
 (1.06 to 1.11) 1944 
1.37  
(1.15 to 1.63) 
0.98 
 (0.87 to 1.09) 
1909 
0.95  
(0.85 to 1.07) 
0.98  
(0.93 to 1.04) 1927 
1.09  
(1.04 to 1.15) 
1.1 
 (1.07 to 1.13) 1945 
1.38 
 (1.15 to 1.65) 
0.93 
 (0.83 to 1.06) 
1910 
0.95  
(0.86 to 1.06) 
0.98  
(0.93 to 1.03) 1928 
1.11  
(1.05 to 1.18) 
1.12  
(1.08 to 1.16) 1946 
1.38  
(1.14 to 1.68) 
0.89 
 (0.78 to 1.02) 
1911 
0.96  
(0.87 to 1.04) 
0.97  
(0.93 to 1.02) 1929 
1.13 
 (1.06 to 1.21) 
1.14 
 (1.1 to 1.18) 1947 
1.39  
(1.14 to 1.7) 
0.85  
(0.73 to 0.98) 
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1912 
0.96  
(0.89 to 1.03) 
0.97  
(0.94 to 1.01) 1930 
1.15 
 (1.07 to 1.24) 
1.15 
 (1.1 to 1.2) 1948 
1.4  
(1.13 to 1.73) 
0.8 
 (0.69 to 0.94) 
1913 
0.96  
(0.9 to 1.02) 
0.97  
(0.94 to 1) 1931 
1.17 
 (1.08 to 1.27) 
1.17  
(1.11 to 1.22) 1949 
1.4 
 (1.12 to 1.75) 
0.76 
 (0.64 to 0.9) 
1914 
0.96  
(0.91 to 1.02) 
0.97  
(0.95 to 1) 1932 
1.19  
(1.08 to 1.3) 
1.18 
 (1.12 to 1.24) 1950 
1.4  
(1.11 to 1.78) 
0.72 
 (0.6 to 0.86) 
1915 
0.97  
(0.93 to 1.01) 
0.97  
(0.95 to 0.99) 1933 
1.21  
(1.09 to 1.33) 
1.19  
(1.12 to 1.25) 1951 
1.41 
 (1.09 to 1.81) 
0.67  
(0.55 to 0.82) 
1916 
0.97  
(0.94 to 1) 
0.98  
(0.96 to 0.99) 1934 
1.23  
(1.1 to 1.37) 
1.19 
 (1.12 to 1.26) 1952 
1.41 
 (1.08 to 1.84) 
0.63 
 (0.51 to 0.79) 
1917 
0.98  
(0.95 to 1) 
0.98  
(0.97 to 0.99) 1935 
1.25 
(1.11 to 1.4) 
1.19 
 (1.12 to 1.27) 1953 
1.41  
(1.06 to 1.87) 
0.59 
 (0.47 to 0.75) 
1918 
0.98  
(0.97 to 1) 
0.99  
(0.98 to 0.99) 1936 
1.26  
(1.12 to 1.43) 
1.19  
(1.11 to 1.27) 1954 
1.41 
 (1.05 to 1.91) 
0.56 
 (0.44 to 0.71) 
1919 
0.99  
(0.98 to 1) 
0.99  
(0.99 to 1) 1937 
1.28  
(1.13 to 1.46) 
1.18 
 (1.1 to 1.27) 1955 
1.42 
 (1.03 to 1.94) 
0.52 
 (0.4 to 0.68) 
      1956 
1.42 
 (1.01 to 1.98) 
0.49 
 (0.37 to 0.65) 
      1957 
1.42  
(0.99 to 2.02) 
0.46 
 (0.34 to 0.61) 
      1958 
1.42 (0.98 to 
2.06) 
0.43 (0.31 to 
0.58) 
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The effect of all parameters, age, period and cohort on hip fractures incidence rates can be 
observed in figure 2, using a GAM analysis. Age effects are similar for both genders, whereas the 
period effect is different: a decrease pattern in women after 2004 and a fluctuation pattern in men. 
The cohort effect, between 1920 and 1940, presents a similar statistically significant pattern in both 
sexes: increasing risk until 1930 followed by a decreasing risk to about 1940; even though the 
patterns are not statistically significant after this point both sexes present an increase, which in 
women is interrupted by another decreasing around 1950. 
 
 
Figure 2: Effect of age, period and cohort on hip fracture incidence rates, 2000-2008, 
modelled by GAM in women and men, relative to the mean rate. 
Some numeric results from GAM models are displayed in table 4. 
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Table 4 – Results from the GAM models for the hip fracture incidence rates in women and 
men, 2000-2008.  
 
 Men Women 
Smooth 
terms 
p-value R-square 
(adjusted) 
Deviance 
explained 
p-value R-square 
(adjusted) 
Deviance 
explained 
s(A) <2×10
-16
 0.927 98% <2×10
-16 
0.968 99.1% 
s(P) 0.0009
 
2.65*10
-6
 
s(C) 2.02×10
-8
 <2×10
-16 
 
The cohort effect in men and women as well as the historical curve of consumers prices 
index and chronogram of political and economic changes in Portugal are displayed in Figure 3, to 
help the discussion of the results. 
 
 
 
Figure 3: Cohort effect in women and men, historical curve of consumers prices index and 
chronogram of political and economic changes in Portugal. 
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Discussion 
A cohort effect on hip fracture incidence rates in Portugal was observed, with risk 
fluctuations in men and women born at times of major political and economic changes: deficient 
nutritional and health conditions in intrauterine life and childhood could be a plausible explanation 
for the increased risk in cohorts born in times of deprivation, and similarly investments on health 
and wellbeing could explain the decreasing in risk in cohorts born in times of political stability. In 
women, this effect was marked by a tendency of risk increasing until 1930, followed by risk 
decreasing (Figures 1 and 2). Even though not statistically significant, there were inflections in the 
risk in 1920 (from stable to increasing), 1940 (from decreasing to increasing), and in 1950 (from 
increasing to decreasing) (Figure 2). Similar results were observed for men except for 1950, when 
the decreasing risk trend was not observed. Women in younger cohorts presented lower risk, while 
for men the estimated risk in younger cohorts was higher (Table 2).  
Regardless of an existing cohort effect, there was a period effect in women with a marked 
turning point in 2004, where the incidence rate decreased. The age effect was similar in both sexes, 
with an exponential-like age increase, as expected and reported in most of the studies. 
The current literature is scarce on studies that analyze the effects of time on the three 
different scales (age, period and cohort) and comparisons must be carefully interpreted because of 
differences in methodologies. Nevertheless, in New Zealand [7] and Sweden [8] a similar 
continuous decrease of risk for younger cohorts was observed, but period effects were opposite, 
with New Zealand showing a continuous increase and Sweden a continuous decrease. Comparisons 
between our results and the Swedish are also difficult because there is an overlay of only three 
calendar years. The age effects were consistent with established knowledge: risk increased 
exponentially with age. Two other studies attempt to report the time effects separately: one used a 
methodology that cannot produce comparable results with ours [26] and another uses data from 
older periods 1968-86 [9].  
Hip fractures can be a consequence of balance between formation and resorption in bone 
tissue through lifetime [4]. Therefore, we can argue that hip fractures are a consequence of lifetime 
exposure, rather than the result of a short-time exposure. The quality of life in youth can be 
especially determinant for the quality of bones, and osteoporosis was until few years ago 
considered a paediatric disease with clinical manifestation in the elderly [27]. Heaney et al (2000) 
[27] described the bone mass life-line where the maximum bone mass potential achieved by 
hereditary factors can be altered by several environmental factors. In addition, intrauterine 
development is determinant in adult bone mass pick [5, 6]; bone growth in uterus demands suitable 
nutrients supplied via maternal food intake: periods of political and economic changes influence 
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population health, and the twentieth century was replete with major conflicts. In Portugal, internal 
changes contributed to the global effects of major conflicts. 
The first three decades of the twentieth century in Portugal were marked by internal and 
external causes of instability, with impact on the population quality of life. Portugal was still 
recovering from the political change from a Monarchy to a Republic (1908-1910) when, in 1914, 
the First World War (WWI, 1914-1918) was declared with Portugal playing an active part with the 
Allies. During the war, in 1917 and 1918 there was a food shortage in Portugal and after that the 
population had to face the Spanish flu (1918 and 1919). The post-WWI period in Portugal was 
marked by increasing inflation, one of the highest in Europe, aggravated by political instability. 
Portugal was amongst the poorest and unhealthiest countries in Europe [28]. See figure 2 (cohort 
effect) for compatible risk alterations in the incidence of hip fractures during these years. 
From 1927 to 1933, a new major political change marked the History of the nation; the 
Republic was replaced by a provisional authority, led by the military, followed by a totalitarian 
regime that lasted 41 years. In the 1930s, the political stability was achieved, finances and economy 
were reorganized and investments were made to construct thousands of elementary schools, 
hospitals, health centres, and infrastructures such as roads, electricity, and sewage. Portugal faced a 
progressive improvement in the general quality of life; Figure 2 (cohort effect) shows compatible 
risk alterations, around this period. 
The decreasing risk of hip fractures observed in cohorts born in the 1930s turned to another 
period of risk increasing after 1940. In spite of the neutral part that Portugal played in Second 
World War (WWII, 1939-1945), there were economic, social and political effects, mainly because 
Portugal depended on belligerent countries’ imports to obtain fuel, industrial primary resources and 
food. After the WWII, there was a boost in the European economy, with the Marshall Plan (1948-
1951); Portugal received the funds in 1949, mostly used to purchase food supplies. In 1952 
Portugal implemented the 1st Foment Plan to elevate the living conditions, improve productivity, 
reduce unemployment [28] and increase the industrialization of the country. At that time Portugal 
was mainly a rural society and the industrialization started a process of rural exodus. Nevertheless, 
Portugal was still among the poorest countries in Europe and the isolation of the totalitarian 
government prevented the country to follow the post-WWII development of the other west 
European countries. The solution to escape poverty, for many Portuguese, was to emigrate. The 
1950s was a period of intense emigration, mainly of young men, especially to France and Germany. 
Their cash remittances helped not only to improve the wellbeing of their families in Portugal but 
also the industrialization of the country. Meanwhile the emigrants themselves were living under 
very poor conditions. This could be a possible explanation for gender risk inequalities for cohorts 
born after 1950 observed in our results: for men, the risk continued to increase while for women it 
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started to decrease. However, data for a longer period needs to be analysed in future studies, in 
order to improve the estimates for younger cohorts. 
Causal effect in epidemiology has been thoroughly discussed and analysed [29]: 
observational studies lack the criteria of causality and therefore results are commonly overlooked. 
It is difficult to attribute causal effects in hip fractures incidence due to the intrinsic nature of bone 
health, reflecting a lifetime of exposures, however our results stressed a number of aspects that can 
be seen as indicators of causality. Besides, there was a reasonable match between the cohort effect 
and historical data of the consumers price index (figure 3, where the historical events were also 
overlaid) which reflects the standard of living and measures the changing costs of purchasing goods 
and services, often used as an indicator of life conditions [30]. It is accepted that conditions during 
the period where bone formation surpasses bone resorption, including intrauterine growth, have 
impacts on bone health later in life [5, 27]. Hence the similar cohort effect observed in both 
genders, with changes in each and every single period of time where a major historical event occurs 
(Figure 2 cohort effect and figure 3), should not be overlooked on the basis of lack of strong 
association, or of disregarding other causal factors. Nevertheless, we are not postulating causality 
neither that the cohort effect is a necessary or a sufficient cause [29] in understanding the trends in 
hip fracture incidence, but it seems an important one to be analyzed in future studies. The 
simultaneity of risk alterations and historical events back the hypothesis of the importance of 
nutrient availability during uterine growth as much as conditions during childhood and 
adolescence. 
The inherent limitations of studies using the APC models, that are related to the 
identifiability problem and invalidate the quantification of the different effects, do not surpass the 
importance of the obtained results. The strength of our study relies on addressing age, period and 
cohort effects simultaneously from several methodology perspectives and using nationwide 
population-based data.  
With this study an innovative perspective on the reasons that drive the trends of hip fracture 
incidence rates is presented, highlighting the considerable differences in the population at risk for 
sustaining a hip fracture. There was a fluctuation on hip risk in both men and women born at times 
of major political and economic changes, regardless of period effects, which could be related to the 
nutritional and health conditions in Portugal at the time. 
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Additional Materials 
 
 
Additional figure 1: Age specific crude incidence rates per 100,000 person-years, for period 2000-
2008 in men. 
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Additional figure 2: Age specific crude incidence rates per 100,000 person-years, for period 2000-
2008 in women. 
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The unaccounted role of macro economic variables: meta-regression 
to explain in-hospital fatality rates following hip fractures 
 
Authors: Sandra Maria Alves, Enrique Goméz-Barrena, Steve Kurtz, Maria de Fátima de Pina 
 
 
Abstract 
Background: Hip fractures have consequences to patients - morbidity and mortality - and to 
health systems - economic burden of surgical treatment and of recovery. The aim of this study is to 
assess if macro-economic variables can explain in-hospital fatality rates following hip fracture, in 
patients aged 50 years-old or more. 
Methods: In-hospital fatality rate was obtained through a systematic review conducted on 
MEDLINE database via PubMed. Studies, published after the year 1999, were included if data for 
in-hospital fatality rates, following a hip fracture admission (ICD-10 S72.0 – S72.2 or ICD-9CM 
820), were available for patients aged 50 years-old or more. Studies of patients with other 
comorbidities (such as cancer) were excluded. Macro-economic and social variables were retrieved 
from Organisation for Economic Co-operation and Development (OECD) and Global Health 
Observatory Data Repository from World Health Organization (WHO). A multiple regression 
analysis was conducted.  
Results: We selected 20 estimates comprising 735,348 hip fractures, from 16 studies, 
developed in 11 countries. The in-hospital fatality rates (%) ranged from 0.7 in Taiwan to 14.0 in 
the United Kingdom; 99.9 of the total variability was due to heterogeneity between studies. The 
density of practicing physicians and of hospital beds explained heterogeneity. 
Conclusions: Heterogeneity of in-hospital fatality rates following hip fractures was partly 
explained by macro-economic variables (including allocation of medical resources) indicating that 
studies on inequalities of health outcomes should not focus only on individual and hospital 
characteristics. 
 
Keywords 
Hip fractures, in-hospital fatality, Bone decade, osteoporosis, meta-regression, health 
resources, outcome 
 
Chapter V   
 
 
 
 
76 
Introduction 
The importance of bone and joint disorders was formally recognised with the launch of the 
Bone and Joint Decade (2000-2010) and osteoporosis was identified as one of the five target 
areas[1]. 
Patients with a hip fracture are at higher risk of mortality compared with the non-hip fracture 
population, and this risk is likely to be elevated through long periods after the incident [2, 3]. It is 
plausible that macro-economic variables, even and national level, can be correlated with mortality 
after hip fractures, since economic constrains have direct implications on health outcomes; 
although studies usually focus only on hospital or patients characteristics, to compare fatality 
between different hospitals [4]. The most common are studies where differences in fatality are 
assessed through the age, gender and co-morbidities of the patients [5-7]. Studies focusing on 
operative management for fractures have also been published [5, 8, 9].  
Fatality may qualify for the ultimately quality indicator, and mortality tables as well as risk 
assessment are currently used. However fair assessments should account for several sources of risk, 
including economical ones.  
The aim of this study is to explore how macro-economic variables, at country level, can 
explain differences between in-hospital fatality rates, following hip fractures, in patients aged 50 
years of age or older. 
 
Materials and Methods 
Data Collection 
Hip fracture data were collected through scientific papers selected by systematic review and 
macro-economic data were obtained through official websites of international organizations. 
 
Hip fracture fatality data 
Data Search 
A systematic review was conducted on MEDLINE database via PubMed during October and 
November of 2010. The search expression, transcribed below, was obtained using analogue 
combinations of Medical Subject Heading (MeSH) terms: hip fracture and mortality. This query 
was supplemented by use of search criteria in All Fields, in order to obtain any other paper that 
might be misclassified in MeSH Terms.  
Manual search was conducted using references of selected studies. In order to obtain a full 
coverage, authors of studies that met the inclusion/exclusion criteria but didn’t exhibit in-hospital 
fatality, were contacted via e-mail in an attempt at gathering more data. 
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("hip fractures"[MeSH Terms] OR "hip fractures"[All Fields] OR "Femoral Neck 
Fractures"[MeSH Terms] OR "Femoral Neck Fractures"[All Fields] OR "femur neck"[All Fields]) 
AND ("hip fractures/mortality"[MeSH Terms] OR "mortality"[MeSH Subheading] OR 
"mortality"[All Fields]) 
 
Study Selection 
Studies were selected if they contained in-hospital fatality data, as a result of admissions 
with hip fracture diagnosis, using the International Classification of Diseases (ICD) codes S72.0 – 
S72.2 (version 10) or 820.x (9th Revision, Clinical Modification). Only studies published in 
English, Portuguese or Spanish, from 2000 through 2010 were considered for analysis.  
Studies were considered when allowing the extraction of data for age groups ≥50 years. We 
excluded experimental, case studies and reviews, as well as studies with one of the following 
characteristics: only patients ≥85; sex-specific; patients with severe pre-existent conditions (such as 
cancer or renal dysfunctions); comparisons of different surgical interventions; less than 200 
fractures; data before 2000 (in order to control for other sources of heterogeneity that could have 
changed over time). 
In-hospital fatality rates, period of data, population, sample size, geographical location, and 
percentage of women patients were variables extracted from eligible studies. 
For each study, macro-economic variables were collected according to geographical location 
and year of data resulting in one estimate per country in the data modelling, except for Canada. 
When studies had data from more than one year, with no possibility of disaggregating it into more 
estimates, macro-economic data were selected for the mid-year of the study period. 
 
Macro-Economic data 
The Organization for Economic Co-operation and Development (OECD) [10] and the Global 
Health Observatory Data Repository from the World Health Organization (WHO) [11] were 
assessed, through the internet, during July 2011 for macro-economic variables at country level. 
Whenever possible data from the OECD were used: otherwise, data from WHO were used to fill 
the gaps. The agreement between the different sources was high. 
After exploratory analysis, four variables, from different themes, were selected: 1 - Private 
expenditure on health as a percentage of total expenditure on health, accounting for the amount of 
expenditure on activities intended to promote health and prevent disease, cure illness and reduce 
premature mortality, on nursing care, provision and administration of public health and health 
programmes. This variable was retrieved from WHO; 2 - Hospital beds, density per 1,000 
population, that accounts for “all hospital beds which are regularly maintained and staffed and 
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immediately available for the care of admitted patients” [10]; 3 - Practising physicians density per 
1,000 population.  OECD was the primary data source for variables 2 and 3 and whenever 
necessary complemented with WHO data; 4 - GINI Income distribution – Inequality, after taxes 
and transfers, for the retirement age population >65, retrieved from the OECD. Higher values of the 
GINI index represent higher inequalities. 
The allocation of GINI to each study was made using the country and the year of data, while 
for all the other variables an arithmetic mean, using values from the five previous years from data 
allocation, was computed, in order to obtain a more accurate measure as these variables may have a 
time-lag effect. 
 
Data Analysis 
Analysis was conducted using R metafor package software [12], with in-hospital fatality 
rates (IHR) as the effect. Since IHR is a proportion, the Freeman-Tuckey double arcsine 
transformed proportion was applied [13]. A weight was applied to each study according to sample 
size - larger sample sizes contributed more to the analysis. 
A random effect model, that allows a different effect for each study [14], was applied to 
quantify the global heterogeneity between studies. The I2 statistics, presented with 95% 
Confidence intervals (CI), was used to assess the proportion of total variability due to heterogeneity 
rather than chance, and may be interpreted as follows: 25%, 50%, 75% indicating low, moderate, 
and high levels of heterogeneity, respectively [14]. Heterogeneity was also assessed, visually, by 
the forest plot (where point estimates, CI, and respective weights used as well as a global estimate 
and CI are displayed) and through the Cochran’s Q test p-value [15]. The global effect of in-
hospital fatality was computed, using the random effect model. 
Potential macro-economic sources of heterogeneity were investigated using a meta-
regression mixed-model; residual analysis was performed to identify possible outliers. R2 measure 
was used to report the proportion of variance explained by the covariates as described in 
Boresntein, 2009 [14]. Positive coefficients indicate a positive direct relationship, where an 
increase/decrease in the explanatory variable leads to an increase/decrease on IHR. Negative 
coefficients on the other hand, represent negative relationships, where the explanatory variables 
vary in the opposite direction of IHR (increase of explanatory variable leads to decrease in IHR, 
and vice-versa). 
To facilitate the reasoning a few IHR were predicted for values of explanatory variables. 
A complete case analysis was performed in the meta-regression models. 
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Results 
An initial search resulted in 1,141 papers. After abstract and full text analysis most were 
excluded as shown in the flow-chart (figure 1), resulting in a total of 16 studies, which met all 
inclusion criteria.  
 
 
Figure 1. Flow-chart illustrating the selection process. 
 
Papers only mentioning hip fractures but not presenting results were classified has non-
specific, whereas recommendations or scale validation papers were classified has no-data or 
methodological.  
Cross-reference search was done but no additional studies were found. The studies eligible 
led to 20 different point estimates, for different countries or data-periods. 
As shown in table 1, studies were conducted in 11 different countries and comprised a total 
of 735,348 cases of hip fractures. 
 
Table 1. Information regarding included studies. 
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Study Data 
period 
Population Sample Size Geographical 
location 
Alvarez-Nebreda 
[16] 
2000-
2002 
All patients hospitalized with an acute hip fracture, aged 65 years or older 
(ICD-9 CM codes 820.0 to 820.9) 
107,718 Spain 
Bergeron [17] 1996-
2003 
All consecutive patients, aged 60 or more operated with an isolated hip 
fracture (ICD-9 codes 820), caused by falls  
906 Canada 
Boufous [18] 1999-
2000 
Patients aged 50 years and over hospitalized with a primary diagnosis of the 
neck of femur (ICD-9 CM codes 820 or ICD-10 codes S72.0- S72.2) 
5,648 Australia (New 
South Wales) 
Cruz [19] 2004-
2006 
All patients aged 50 and over hospitalized with a proximal femur fracture 
after a low impact fall 
267 Portugal (Caldas da 
Rainha) 
Haaland [20] 2003-
2004 
Patients aged 50 or over hospitalized with a low-impact hip fracture, 
excluding pathological fractures due to malignancy or intrinsic bone disease 
342 Canada (Ontario) 
Hagino [21] 1997- 
2004 
Patients aged 60 and over hospitalized with a hip fracture 290 Japan (Yamanashi) 
Hindmarsh [22] 2000-
2003 
Patients aged 65 or older hospitalized with the principal diagnosis of hip 
fracture (ICD- 10- AM codes S72.0- S72.2) caused by unintentional falls 
16,836 Australia (New 
South Wales) 
Lefaivre [23] 1998- All patients over the age of 65 hospitalized with an isolated fracture of the 607 Canada 
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2001 proximal femur (Vancouver) 
Morosano [24] 2001-
2002 
Patients aged 50 or over hospitalized with a hip fracture 763 Argentina 
(Rosario) 
Nielsen [25] 2005-
2006 
All patients hospitalized with only one episode of hip fracture within the 
period, over 64 years of age 
6,266 Denmark 
Pereira [26] 2001 Patients aged 60 or over admitted with a femoral neck or intertrochanteric 
fracture caused by falls, excluding cancer.   
246 Brazil (Rio de 
Janeiro) 
Söderqvist [27] 2003 All patients aged 66 or over with a hip fracture, excluding pathologic 
fractures 
1,944 Sweden 
(Stockholm) 
Shao [28]  1996-
2002 
Patients over 64 years of age, admitted with a hip fracture (codes ICD-9 820) 
who underwent surgery, excluding pathological fractures 
75,482 Taiwan  
Vidal [29] 2003-
2004 
All patients, aged over 59, admitted to hospital, with a main diagnosis of hip 
fracture (ICD-9 codes 820), excluding cancer, high impact trauma  
3,754 Canada (Quebec) 
Wu [30] 1998 - 
2009 
All patients admitted to hospital with a main diagnosis of hip fracture (aged 
45 or over) (ICD- 10 codes S72.0, S72.1, S72.2) 
551,976 England 
Yonezawa [31] 2003-
2006 
All patients admitted to hospital with a hip fracture, aged over 60 536 Japan (Kanagawa) 
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In-hospital case fatality rates (IHR) ranged from 0.6% in a study conducted in Taiwan [16] 
to 14.0% in the United Kingdom [17] and this heterogeneity is displayed in the forest plot (figure 
2). In this figure we can also observed the weights attributed to each of the studies. The percentage 
of total variability due to heterogeneity rather than sampling error (I2) was 99.9% (95% CI 99.84 – 
99.96) and the global estimate for in-hospital case fatality rate was 5.6 (95% CI 3.8% - 7.7%). 
Cochran’s Q test p-value was < 0.001 concluding that not all estimates share a common effect. 
Only four studies presented data by gender (table 2) so no analysis was conducted separately 
for each sex. And as expected, all studies reported higher fatality rates for men. 
 
Figure 2. Forest plot with IHR estimates and global effect. 
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Only 4 studies presented data by gender (table 2) so no analysis was conducted separately for 
each sex. And as expected, all studies reported higher fatality rates for men. 
 
Table 2. Information regarding IHR and other variables by study. 
 
Study Allocated year 
of data 
Gender 
Composition 
In-hospital fatality rates 
Women Men Total 
Alvarez-Nebreda 
[16] 
2001 Women (74.3%) 4.8% 8.9% 5.9% 
Bergeron [17] 2000 NA NA NA 12.7% 
Boufous [18] 2000 Women (73.4%) NA NA 5.1% 
Cruz [19] 2005 Women (76%) NA NA 3.7% 
Haaland [20] 2004 Women (74.9%) NA NA 8.5% 
Hagino [21] 2001 Women (79.7%) NA NA 4.5% 
Hindmarsh [22] 2002 Women (74.9%) 3.4% 7.4% 4.4% 
Lefaivre [23] 2000 Women (79%) 5.8% 16% 7.9% 
Morosano [24] 2002 Women (79.7%) NA NA 1.4% 
Nielsen [25] 2006 Women (73.8%) NA NA 5.1% 
Pereira [26] 2001 Women (72.8%) 6.1% 16.4% 8.9% 
Söderqvist [27] 2003 Women (74.7%) NA NA 4.0% 
Shao [28] 2000 Women (61.1%) NA NA 0.8% 
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 2001 Women (59.8%) NA NA 0.7% 
 2002 Women (61.3%) NA NA 0.8% 
Vidal [29] 2004 Women (79.8%) NA NA 9.0% 
Wu [30] 2000 NA NA NA 13.0% 
 2004 NA NA NA 14.0% 
 2007 NA NA NA 12.0% 
Yonezawa [31] 2005 Women (83%) NA NA 4.1% 
 
 
Availability of explanatory variables were: Private expenditure on health as a percentage of 
total expenditure on health (available for 17 estimates; minimum 15.9 in Sweden [18], maximum 
58.2 in Brazil [19], mean 27.4, SD 10.9), Hospital beds density per 1,000 population (available for 
15 estimates; minimum 2.7 in Brazil [19], maximum 15.0 in Japan [20], mean 5.3, SD 3.7), 
Practising physicians density per 1,000 population (available for 17 estimates; minimum 1.3 in 
Brazil [19], maximum 3.5 in Portugal [21], mean 2.3, SD 0.6) and finally GINI (available for 15 
estimates; minimum 0.2 in Denmark [22], maximum 0.328 in Portugal [21], mean 0.28, SD 0.05). 
The results from the simple meta-regression models are presented in table 3, whereas the 
multiple meta-regression model on table 4. 
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Table 3: Simple meta-regression models 
 
Table 4. Multiple meta-regression model. 
 
The predicted (multiple model) In-Hospital Fatality Rate (IHR) for densities of 5.3 for 
hospital beds and 1.5 for practising physicians is 10.7%. Whereas the predicted IHR for densities of 
5.3 for hospital beds and 2.5 for practising physicians is 6.4%.  
Predicting from the multiple meta-regression model, considering the densities of 5.3 for 
hospital beds and 1.5 for practising physicians the prediction for In-Hospital Fatality Rate (IHR) is 
10.7%. Whereas values of 5.3 and 2.5 for the densities of hospital beds and practicing physicians, 
respectively, corresponded to a prediction of 6.4% in IHR. 
Variable Coefficient 
estimate 
95% CI P-value R
2 
Practising physicians density per 
1,000 population 
-0.08 (-0.13 to -
0.03) 
<0.01 35.8% 
Hospital beds density per 1,000 
population 
-0.01 (-0.01 to 0.00) 0.21 2.3% 
GINI -0.40 (-1.16 to 0.36) 0.30 0.0% 
Private expenditure on health as 
a percentage of total expenditure 
on health 
-0.00 (-0.00 to 0.00) 0.45 0.0% 
 Coefficient 
estimate 
95% CI  P-value R
2
 
Intercept 0.53 (0.38 to 0.63) <0.01 48.7% 
Practising physicians density 
per 1,000 population 
-0.08 (-0.12 to -0.03) <0.01 
Hospital beds density per 1,000 
population 
-0.01 (-0.02 to -0.00) 0.01 
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Discussion 
The differences observed on in-hospital fatality rates (IHR), following a hip fracture, could 
be partly explained by the differences on resources (density of practising physicians and density of 
hospital beds). 
Our results can assist decisions on resource allocation as the economy is facing serious 
challenges and resources are being carefully managed. A balance between immediate and long-
term savings is necessary before decisions are made - investments on health resources, such as 
number of physicians or hospital beds, have impact on fatality. Our results also highlight the 
importance of considering other variables, aside from patient or hospital characteristics, in the 
understanding of in-hospital fatality variability following hip fractures. Outcome measurements 
such as mortality have been recognised as the ultimate quality measurement of treatment in many 
conditions. A feasible indicator should be analysed thoroughly, at every possible perspective. All 
sources of heterogeneity should be adjusted and accounted for.  
The reasons for the observed differences in the fatality rates can be the result of a number of 
different factors related to individual characteristics [3], namely age and sex. The inability of 
having individual data regarding the health status of the patients at the time of fracture treatment 
makes it impossibility for meta analytic studies to study both individual and macro variables 
together. However, the information on the health status of the individuals can be somehow 
measured by the availability of health resources for the population. In this sense, the results 
obtained are quite intuitive, higher density of resources leads to less in-hospital fatality. The 
availability of practising physicians can act on the general health status of the population and, 
specifically, can also lead to better monitored elderly, which are usually a population with chronic 
conditions, and subject to the intake of many different medications [23], having a positive effect on 
mortality; This positive effect can also be the result of a decrease time to surgery [24] due to the 
availability of physicians and hospital beds. 
The study presents some limitations that do not invalidate the results. The use of fatality 
rates as the effect in meta-analytic studies may be considered inadequate since it may reflect the 
influence of many other variables. However, the aim of this work was not to produce a global 
estimate on the IHR, but to model the influence of factors of heterogeneity usually disregarded. 
The number of possible factors of heterogeneity had to be limited due to a problem that the 
majority of meta-analytic studies face, the small number of studies selected. 
The strengths of our study lies in the innovative methodological approach that is being 
proposed where part of the heterogeneity in IHR following hip fractures could be explained by 
macro-economic variables, with impacts on both resource allocation and risk adjustment. The 
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results achieved by the systematic review, conducted in MEDLINE, also provide a valuable insight 
on the IHR during the Bone and Joint Decade. 
 
Conclusions 
Unfavourable outcomes, like in-hospital fatality following a hip fracture can be explained by 
differences in macro-economic variables, such as allocation of medical resources. The current 
economic crisis is leading to cuts in public investments in health, in some countries, including 
Portugal. Studies such as ours are useful not only for the purpose of understanding fatality 
following hip fractures but also as a public-health indicator identifying the importance of health 
investments. 
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Abstract 
Background: The increase number of elderly is aggravating the demand on health systems 
caused by hip fractures treatment. Fatality can be used an indicator for quality of treatment. The 
aims are: obtain a risk adjustment and compare hospital effect on the probability of dying during a 
hospitalization for hip fracture. 
Methods: We used a multilevel (patient/hospital/area) Bayesian approach. The outcome 
measure was in-hospital fatality; patient level factors were collected from the National Hospital 
Discharge Register; hospital level factors form the National Hospital Inquiries and area level 
factors from Statistics Portugal. 
Results: Data from 47 hospitals (45 areas) treating 53,684 hospitalizations was used. 
Variables with significant association with the probability of dying, after adjustment for overall 
fatality in hospital and orthopedic ward, were (log scale 95% Credible intervals): age (0.07 (0.06 to 
0.07)), sex (0.72 less for women (-0.80 to -0.63)), length of stay -0.01 (-0.02 to -0.01), severity 
(highest versus lowest category (2.50 (2.30 to 2.71))), conservative treatment had a highest 
increased in probability of dying versus other treatments, except internal fixation. Delay in surgery 
was not a statistically significant effect, except compared to no surgery category. The overall effect 
of time in the probability of dying was not statistically significant (-0.02 (-0.06 to 0.00)). However 
some hospitals did present improvements. 
Conclusions: In spite of the difficulty of assessing quality of care, multilevel approach seems 
a better solution. Our results point that improvements made in the population health status can have 
positive impacts on improving in-hospital probability of dying. 
 
 
 
 
 
 
 
Chapter VI  
 
 94 
Keywords 
 
Hip fractures, osteoporosis, treatment outcome, in-hospital fatality, adjustment, 
population-based study 
 
 
Introduction 
The advances in medicine and the improvement of the general wellbeing led to an increase 
of life expectancy [1] and consequently to more population at risk of hip fractures with impact on 
individuals (increase morbidity and mortality - especially in the first three months) and on societies 
(costs of treatment and recovery [2-4]). Even though a decrease in the trend of hip fracture 
incidence rate have been reported [5-7], the total number of fractures is increasing, leading to high 
demand for treatment at orthopedic wards, stretching the resources and compelling changes without 
compromising outcomes [8].  
In-hospital outcomes, such as fatality rates, can be used as reliable indicators to measure and 
improve quality of care and allowing fair comparisons between providers. Outcome is a function of 
quality of care and other covariates, namely intrinsic characteristics of patients [9]: therefore, to 
obtain fair indicators, sources of variation need to be removed through risk adjustment models - 
residuals reflecting the quality of care. Risk adjustment refers to factors such as delay of surgery, 
nutrition, delirium, patient characteristics, intervention of interdisciplinary teams and hospital 
volume [10-13]. Although, adjust for all characteristics [14] may be difficult to achieve reliable 
results it is necessary to account for different sources of variation. Our study is innovative because 
we account for different sources of variation within a single model, allowing a holistic view of 
quality of care. 
The aims of this study are: 1- to obtain a risk adjustment for hip fractures in-hospital fatality 
rate and 2- to compare the probability of in-hospital fatality rate, from 2000 to 2008. 
 
 
 
Methods 
The study area was Continental Portugal, which had 3,298,922 inhabitants over 49 years old 
in 2001[15]. The coast area concentrated 70% of the population and the higher density and most 
specialized hospitals. 
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Data 
We accounted for different sources of variation to obtain an unbiased indicator, and 
classified the data into 3 hierarchical levels: patients, hospitals and (spatial) areas.  
In-hospital fatality was the outcome measure; the list of variables (and sources) used for risk 
adjustment, by level, is in Table 1. 
 
Table 1- Variables used to adjust for the risk in-hospital fatality, by level, and source. 
 
Level Variable Source 
Patient Age (years) National Hospital Discharge  
Register 
 (NHDR) 
Sex (men/women) 
Length of stay (LOS) 
Transfer (yes/no) 
Treatment (conservative/internal fixation/without 
internal fixation/ partial arthroplasty/ total 
arthroplasty) 
Time to surgery (zero days/1 day/2 days/>2 
days/no-surgery) 
Severity – Charlson Index (0/1/2/3/>3) 
Hospital Number of hospitals within a 30 Kilometres radius  -  
 Classification (Group 2/4/5) Official classification for financial 
proposes [18] 
 Volume (number of patients treated for hip fracture) NHDR 
 Proportion of beds in orthopaedic wards from the 
total number of beds 
National Hospital Inquiry (NHI) 
 Proportion of orthopaedic medical staff from the 
total number of medical staff 
 Proportion of patients dead in the hospital from the 
total number of patients that left the hospital 
 Proportion of patients dead in the orthopaedic ward 
from the total number of patients that left the 
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orthopaedic ward 
 Number of orthopaedic surgeries (large and medium 
size) 
Area Average number of medical consultations in health 
centres by habitant 
Health Statistics- available at National 
Institute of Statistics (Instituto Nacional de 
Estatística – INE [17])  Number of nurses per 1,000 habitants 
 Number of pharmacies per 1,000 habitants 
 Number of resident medical doctors per 1,000 
habitants  
 Proportion of private hospitals from the total 
number of hospital in the area 
 
All variables from patient level and volume of admissions from hospital level were retrieved 
from the National Hospital Discharge Register NHDR. The use of this administrative database is 
mandatory since 1997 in all Portuguese public hospitals, and compiles information such as gender, 
age, admission and discharge date; causes and diagnosis (up to 20) of admission coded according to 
the International Classification of Diseases, version 9, Clinical Modification (ICD9-CM); clinical 
and surgical interventions; hospital providing the care; outcome; length of stay (LOS) and the 
patient place of residence.  
In Portugal, access to the national health-care system is universal and tendentiously free-of-
charge. Therefore hip fractures are highly documented and the NHDR records the total number of 
admissions with a diagnosis of hip fracture nationwide. The quality of the NHDR is assessed 
regularly by both internal (hospitals) and external (ACSS- Central Administration of the National 
System) auditors [16]. 
All discharges from 1 January 2000 to 31 December 2008, from individuals aged 50 years or 
over with diagnose of hip fracture (codes ICD9-CM 820.x), caused by low or moderate trauma, 
were selected. We excluded cases of bone cancer, readmissions for orthopedic after-care or 
complications in surgical and medical care (codes ICD9-CM: 170.x, 171.x, V54.x and 996.4).  
Co-morbidities, registered in the NHDR, were integrated in the model through the use of the 
Charlson Index, a co-morbidity index calculated using the scoring system [17] presented in 
Additional Table 1. The delay to surgery was calculated as the time (days) between admission and 
surgical treatment. 
Variables from hospital level were mainly associated with structure and expertise. We 
included the official classification of hospitals that uses the average cost of patient, and that 
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classifies the hospitals into 5 different groups (1 to 5, decreasing cost). Hospitals treating hip 
fractures are classified as one of the groups 2, 4 or 5 [18].  
To avoid the small numbers statistical instability, we excluded 26 hospitals (accounting for 
1,244 hospitalizations) that treated on average less than 50 fractures by year. During the study 
period the National Health Service (NHS) was restructured, with the association of some hospitals 
in Hospital Centres. We excluded admissions in such Hospital Centres (after the restructure), 
because it was not possible to link the hospitalization with the resources.  
Data at hospital level was obtained from the National Hospital Inquiry (NHI), which is 
annually conducted by the Statistics’ Portugal (INE). For reasons of confidentiality, the NHI 
doesn’t explicitly identify the hospitals, although based on some variables (for municipality, size 
and type of hospital) we were able to identify most of them, except four hospitals in the Lisbon 
area accounting for 7,365 admissions that were excluded. For the implementation of the statistical 
model, 47 hospitals from 45 different municipalities (areas) were used. All included areas had at 
least one hospital that treats hip fractures; however they can differ in terms of number of health 
equipments and/or performance. Variables were retrieved from INE. 
Statistical analysis 
A multilevel (hierarchical) statistical model for the binary outcome (dead/survival) was used 
to obtain a risk adjustment at patient level and that also for comparison between providers. 
We used the natural hierarchical structure of the data to model the probability of survival: 
patients were nested in hospitals that in turn were nested in areas – a three level model. Patients 
treated in the same hospital may have similar individual characteristics - therefore they are 
dependent events, and so are hospitals located in the same municipality. Theses facts were taken 
into account in the statistical model; failing to account for this specificity could have lead to invalid 
results [19]. Multilevel models allowed simultaneous analysis of the group-level and individual 
level predictors (correcting for the biases in parameter estimates resulting from dependencies) and 
decomposition of the outcome at each level [20, 21]. 
We used a Bayesian approach, using Markov Chain Monte Carlo (MCMC). Prior beliefs 
about unknown parameters were incorporated in the form of prior distributions and then updated by 
information in the data to give posterior distributions, which expresses all the uncertainty about 
each parameter. Posterior distributions were used to calculate point estimates (e.g. mean, median, 
mode), standard deviations and 95% credible intervals (95%CI) [19].  
Suppose that yijk is the outcome (0 = survival/1 = death) of patient i treated in hospital j in 
area k and that pijk is the probability of death during hospitalization for hip fracture. The model 
used is: 
Patient level 
yijk ~Bernoulli(pijk) 
logit(pijk)=beta0+beta1agei+beta2sex+alphajyeari+beta3LOSi+beta4transferi+beta5severity+ 
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beta6treatment+beta7timetosurgery+Psijk 
 
where i=1,…,53684 patients, j=1,...,47 hospitals and k=1,…,45 areas.  
Note, 
 logit(pijk)=log(pijk/(1- pijk)) 
 
Hospital level 
Psijk=gamma0j+gamma1number_hospitalsj+ gamma2classificationj+gamma3volumej+ 
gamma4beds+gamma5medicalj+gamma6hosp_fatalj+gamma7orto_fatalj+ 
gamma8orto_surgj +thetak 
j~ N(, 
2
) 
gamma0j ~N(0, 
2
) 
Area level 
thetak=delta0k+delta1med_consulk+delta2nursesk+delta3pharmaciesk+delta4doctorsk+ 
delta5privatek 
delta0k~N(0, 
2
) 
 
All ‘global’ parameters associated with various explanatory variables, namely betam, gamman 
and deltap for m=1,..,6, n=1,…,8 and p=1,…,5, were given a Gaussian prior distribution with zero 
mean and variance 1000. Such Gaussian priors are uninformative in the sense that they effectively 
express our belief that the parameter can take any positive or negative value with approximately 
equal probability. For variance parameters 2, 2 and 2 and more specifically their inverse, we 
assumed gamma distributions with mean 100 and variance 20,000. Such a gamma distribution for 
the inverse of a variance parameter is also uninformative and restricts values to the positive real 
line. 
The model was implemented using WinBUGS software [22] combined with the statistical 
software R version 2.15.2 (The R Foundation for Statistical Computing) and specifically the R 
package R2WinBUGS. Using those samples, we calculated the posterior mean as a point estimate 
for each parameter.  95% Credible Intervals (CI) were obtained by calculating the 2.5% and 97.5% 
empirical quantiles of the posterior samples. The posterior means can be interpreted as the 
multiplicative effect on the Odds Ratio (OR) of each explanatory variable. Identification of 
statistical significant coefficients will be done looking for 95% CI that do not contain zero. Positive 
credible intervals will have positive effect on OR, increasing the OR. Negative credible intervals 
will have negative effects on OR, decreasing the OR. 
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Results 
After exclusions, 53,684 hospitalizations were used for fitting the model, from 47 different 
hospitals in 45 different areas, during the period of 2000-2008 in Portugal. On average, women 
were older at time of hospitalization (mean 81.0 years (8.5 SD) versus mean 78.1 years (10.1 SD) 
in men) and accounted for 41, 389 hospitalizations (77.1%). The overall in-hospital fatality rate 
was higher in men 9.1% compared to women (4.9%) (p-value <0.001). In 5,538 (10.3%) of the 
hospitalizations the treatment was conservative (no surgery). Characteristics of the patients, 
disaggregated by outcome, are displayed in table 2. 
 
Table 2: Patient level characteristics at baseline, by outcome. 
 
Variable   Dead Alive p-value 
Age (Mean (SD))   84.0 (7.8) 80.1 (9.0) <0.001 
Sex (% in sex) Men 1,115 (9.1%) 11,180 (90.9%) <0.001 
Women 2,011 (4.9%) 39,378 (95.1%) 
LOS (Mean (SD))   14.6 (13.7) 15.3 (19) 0.038 
Transfer (% in 
transfer) 
Yes  250 (5.4%) 4,368 (94.6%)  0.214 
No 2,876 (5.9%)  46,190 (94.1%)  
 Severity (% in 
severity) 
 0  1,574 (3.8%) 39,526 (96.2%)  <0.001 
1 577 (14%) 3,554 (86%) 
2 550 (8.3%) 6,507 (91.7%) 
3 234 (20.4%) 914 (79.6%) 
>3 191 (27.4%) 507 (72.6%) 
Treatment (% 
treatment) 
Conservative 1,371 (24.8%) 4,167 (75.2%) <0.001 
Internal 
fixation 
14 (11.1%) 112 (88.9%) 
Without 
internal 
fixation 
1,125 (3.5%) 31,239 (96.5%) 
Partial 527 (4.4%) 11,490 (95.6%) 
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arthroplasty 
Total 
arthroplasty 
89 (2.4%) 3,550 (97.6%) 
Time to surgery (% 
Time in surgery) 
Zero days 518 (3.7%) 13,481 (96.3%) <0.001 
 1 day 273 (3.5%) 7,517 (96.5%) 
2 days 176 (4%) 4,244 (96%) 
> 2 days 788 (3.6%) 21,149 (96.4%) 
No surgery 1,371 (24.8%) 4,167 (75.2%) 
 
Hospitals characteristics varied greatly (Additional Figures 1, 2, 3 and 4) and the amount of 
treated fractures, in the period, ranged from 206 to 3,200 per hospital. 
 
The left panel of Figure 1 plots the in-hospital fatality rate in the nine-years period for each 
hospital (95% Confidence Intervals). The lowest rate observed was 2.95 per 100 (1.37 to 4.53) and 
the highest observed was 11.85 (8.91 to 14.79). The central panel in Figure 1 shows, at the logit 
scale, the hospital effect (gamma0j) on the in-hospital probability of dying. Negative estimates 
represent lower probabilities; positive estimates represent higher probabilities of dying. All 95% CI 
contained zero so one may argue that none of the effects are significantly different from zero, 
however some hospitals have a noticeably different effect than most of the others, for instance the 
negative effect of hospital 11 and the positive effect of hospital 19. Note the difference in the left 
and centre panels of Figure 1, which is due to the model accounting for patient and area 
characteristics in the data. The model effectively indicates that the hospital effect in the probability 
of dying is effectively constant over Portugal if one accounts for individual patient characteristics 
and the area effect.  
Finally, the rightmost panel in Figure 1, shows the effect of time (alphaj) on the probability 
of dying (pijk) where we can observe that some hospitals have negative estimates (e.g. hospital 5, 9, 
35, 44, 47), indicating a decrease on the probability of dying with time for that hospital.. 
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Figure 1: Leftmost plot is the In-hospital fatality crude rates by hospital with 95% 
Confidence Intervals; Centre plot the Hospital effect on the in-hospital probability of dying with 
95% Credible Intervals, estimated from the model; Rightmost plot is the time effect on in-hospital 
probability of dying with 95% Credible Intervals, estimated from the model. 
Table 3 displays estimates and 95% credible intervals for the parameters associated with all 
explanatory variables in the data. 
 
Table 3: Fixed effect-estimates from the model in log odds scale and variances 
 
Level Variable   Coefficient SD  Estimates 
(95% Credible Intervals) 
Patient (Intercept)  beta0 0.759 -8.090 (-9.683 to -6.558) 
Age    beta1 0.003 0.067 (0.065 to 0.073)  
Sex (% in sex) Men beta2  Ref 
Women 0.044 -0.718 (-0.804 to -0.631) 
LOS (Mean (SD))   beta3 0.0018 -0.013 (-0.017 to -0.010) 
Transfer (% in transfer) Yes beta4  Ref 
No 0.080 -0.021 (-0.179 to 0.134) 
 Severity (% in severity)  0 beta5  Ref 
1 0.059 1.308 (1.191 to 1.423) 
2 0.058 1.061 (0.948 to 1.172) 
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3 0.089 2.052 (1.876 to 2.227) 
>3 0.106 2.505 (2.287 to 2.714) 
Treatment (% treatment) Conservative beta6  Ref 
Internal fixation 0.340 -0.011 (-0.071 to 0.63) 
Without internal 
fixation 
0.149 -1.263 (-1.539 to -0.969) 
Partial 
arthroplasty 
0.153 -1.066 (-1.347 to -0.764) 
Total 
arthroplasty 
0.185 -1.140 (-1.493 to -0.774) 
Time to surgery (% Time in 
surgery) 
Zero days beta7  Ref 
1 day 0.081 -0.156 (-0.317 to 0.0003) 
2 days 0.094 -0.016 (-0.202 to 0.166) 
> 2 days 0.065 -0.065 (-0.192 to 0.065) 
No surgery 0.155 1.000 (0.711 to 1.309) 
Hospital Number of hospitals within a 
30 Kilometres radius 
 gamma1 0.021 0.026 (-0.017 to 0.069) 
Classification  2 gamma2  Ref 
4 0.022 -0.032 (-0.461 to 0.407) 
5 0.347 0.188 (-0.543 to 0.839) 
Volume   gamma3 8 e
-4
 -3 e
-4
 (-0.002 to 0.001) 
Proportion of beds in 
orthopaedic wards in the total 
number of beds 
 gamma4 0.979 -0.864 (-2.850 to 0.970) 
Proportion of orthopaedic 
medical staff in the total 
number of medical staff 
 gamma5 1.064 0.533 (-1.503 to 2.707) 
Proportion of patients dead in 
the hospital in the total 
 gamma6 3.144 7.093 (1.073 to 13.470) 
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The variables at area level presented non-significant results and none of the areas presented a 
differentiated effect on the probability of dying (additional figure 5). 
 
number of patients that left the 
hospital 
Proportion of patients dead in 
the orthopaedic ward in the 
total number of patients that 
left the orthopaedic ward 
 gamma7 3.606 24.771 (17.620 to 31.740) 
Number of orthopaedic 
surgeries (large and medium 
size) 
 gamma8 8.322e
-5  
 6.291e
-5
 (-1.20e
-4
 to 2.156e
-4
) 
Area Average number of medical 
consultations in health centres 
by habitant 
 delta1 0.226 0.236 (-0.240 to 0.635) 
Number of nurses per 1,000 
habitants 
 delta2 0.050 8.213e
-4
 (-0.108 to 0.087) 
Number of pharmacies per 
1,000 habitants 
 delta3 1.048 -1.480 (-3.427 to 0.615) 
Number of resident medical 
doctors per 1,000 habitants  
 delta4 0.0545 -0.010 (-0.105 to 0.104) 
Proportion of private hospitals 
in the total number of hospital 
in the area 
 delta5 0.381 0.024 (-0.730 to 0.781) 
Variances Between hospitals   tau gamma0 0.044 0.071 (0.015 to 0.177) 
Between areas   tau delta0 0.051 0.081 (0.016 to 0.204) 
Between hospital/time   tau_beta3 0.002 0.007 (0.004 to 0.011) 
Overall effect of time on the 
probability of dying  
 nu 0.018 - 0.027 (-0.062 to 0.008) 
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Discussion 
Our results revealed that the differences observed in in-hospital fatality rates can be 
explained by patient individual characteristics and their underlying health status but also by 
variables related to the quality of treatment. That is, if hospitals treating patients with the same 
profile had the possibility to undertake surgery within the same time lag and provide surgical 
treatment to all patients, they would all have the same impact on the probability of dying. Our 
results identify that the opportunities to improve in-hospital fatality lie in the improvement of 
general health status of the individuals and in the increase of surgical treatment. 
All providers, after adjustment, had a similar effect on the probability of dying. Nevertheless, 
we were able to identify some hospitals that improved during the study period. The use of a 
multilevel model incorporating various sources of variation to adjust the probability of in-hospital 
fatality allowed a more robust comparison between providers and the identification of the trend of 
in-hospital fatality by provider, even if no hospital or area effect could be identified.  
Our interpretation of the care provided to hip fracture was based on the three-way approach 
to quality proposed by Donebedian [23, 24], where quality of care should be evaluated using 
structure, process and outcome indicators, stringed because “good structure increases the likelihood 
of good process, and good process increases the likelihood of a good outcome” Donabedian (1988). 
Our model incorporated outcome, process and structure components. After adjustment for patient 
characteristics and health status, variables related to process such as time to surgery and treatment 
were still determinant for better outcomes. Our results only showed an increased effect on the 
probability of dying when comparing no surgery with undertaking surgery on the day of admission 
(reference). Studies reported that after adjusting for confounding factors, no effect of time to 
surgery was identified [25]. However, accumulated evidence seems to favour earlier surgery 
associating it with lower risk of death, lower rates of postoperative complications and reduced 
length of stay [11, 26]. Patients that are treated conservatively were identified as having higher risk 
of in-hospital fatality, in agreement with other studies and guidelines [27-29].  
Resources were incorporated through variables at hospital level, such as beds or medical 
staff in orthopedic ward. However, the effect of these variables was not statistically significant. The 
area level variables were proxy measures of the influence of areas more capable of providing 
healthcare. However, no significant area effect was identified. 
Other procedures that were not measured in this study, like early assessment of patients’ 
nutritional risk, systematic pain assessment during mobilization evaluated in other studies [30] or 
recommended thromboprophylaxis [27, 29] can have impact on the probability of dying during 
hospitalization but are unlikely to significantly explain differences between providers, because 
hospitals seem to have the same effects after adjustment for the measured variables. Nevertheless, 
assessments regarding other processes and outcome measures could be vital to understanding the 
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improvements observed in some hospitals, during the study period, but no such data were available 
for our study. The multidimensional nature of healthcare makes the measurement of quality 
difficult. Improvements in the probability of dying during hospitalizations for hip fractures can be 
due to a wide variety of factors, directly associated with hospital performance: changes in pre-
operative (e.g. with early stabilization of the patient) and in pos-operative treatment (eg. with 
nutritional assessment and treatment or a multidisciplinary approach to recovery) [23, 24]. 
Conservative treatment, although identified as a risk factor in the probability of dying, can be 
related to bad hospital procedures but also to personal choices of patients. The adequate treatment 
of the very old (nonagenarians and centenarians) is still under discussion [31-33], and families may 
decide that their relatives should not face the consequences of surgery.  
As expected, the effects of age, sex and severity were similar to what other studies described 
[34]; the gender difference, which prevail after the adjustment for severity index was similar to 
other studies. The reasons for differences in gender remain unclear even after adjusting for 
medications [35]; the infection has been pointed as possible cause for the differences [36]. 
The national scope, incorporating hospitals where 70% of hip fractures were treated in 
Portugal is one of the strengths of our study. The other strength relies on the appropriate multilevel 
approach. The common approach to profile providers has been to predict the outcome at individual 
level, calibrate the process to use it on a different provider, and compare observed and predicted 
outcome for each provider [37, 38]. The hierarchical approach using patients at level I and hospital 
at level II, allowed us to predict outcome at individual level and a comparison between providers 
simultaneously. Limitations are mostly related to data sources; the impossibility of database 
linkage between different health databases in Portugal prohibits the use of mortality after discharge. 
The use of administrative databases restrains the possibility of studying different outcomes, such as 
functional recovery, important because studies have shown that providers may have good 
performances in one outcome and bad performances on others [39].  
After adjusting for confounding factors, hospitals from the National Health System in 
Portugal do not seem to have a differentiated effect on the probability of dying in patients 
hospitalized for hip fracture. To improve fatality outcome, health care systems should address the 
general health of population. 
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Additional Materials 
 
Additional Table 1- Scoring system to calculate the Charlson Index 
 
Weights Conditions ICD-9 CM 
codes 
Weights Conditions ICD-9 CM 
codes 
1 Myocardial infarct 410, 411 2 Hemiplegia 342, 434, 436, 
437 
Congestive heart failure 398, 402, 428 Moderate or several renal 
disease 
403, 404, 580-
586 
Peripheral vascular 
disease 
440-447 Diabetes 250 
Dementia 290, 291, 194 Any tumor 140-195 
Cerebrovascular 
disease 
430-433, 435 Leukemia 
 
204-208 
Chronic pulmonary 
disease 
491-493 Lymphoma 200, 202, 203 
Connective tissue 
disease 
710, 714, 725 3 Moderate or several liver 
disease 
070, 570, 572 
Ulcer disease 531-534 6 Metastatic solid tumor 196-199 
Mild liver disease 571, 573    
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Additional figure 1: Differences in annual averages by hospital of Proportion of beds in 
orthopaedic ward in total number of beds and Proportion of orthopaedic medical staff in total 
number of medical staff. Outliers are identified. 
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Additional figure 2: Differences in annual averages by hospital of Proportion of patients 
dead in the hospital in the total number of patients that left the hospital and Proportion of patients 
dead in the orthopaedic ward in the total number of patients that left the orthopaedic ward. Outliers 
are identified. 
 
 
Additional figure 3: Differences in annual averages by hospital of Volume. 
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Additional figure 4: Differences in annual averages by hospital of Number of orthopaedic 
surgeries (large and medium size). 
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Additional figure 5: Area effect on the in-hospital probability of dying with 95% Credible 
Intervals, estimated from the model 
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General Discussion, Conclusions and perspectives 
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In this population-based retrospective study, the year 2003 appeared as a turning point in the 
time trend of age-standardized incidence rates (ASIR) of hip fracture in women. The observed 
trend from 2000-2008 with a clear and abrupt decrease change in 2003, is compatible with an 
intervention on national level. A change in the trend could be attributed to a number of different 
factors, however it is unlikely that a change in the demographic and socioeconomic characteristics 
of the population could occur so promptly that impacted on hip fracture incidence so abruptly has 
the results pointed out.  
In order to further investigate the intervention responsible for the prevention of hip fracture, 
the number of anti-osteoporotic medication packages sold in Portugal, in each year of the study 
period was analyzed. The results were similar: the same impact on the trend of ASIR for women, 
with the same turning point relating to 2003 sales. Other interventions, such as falls prevention 
campaigns, are usually focused on the elderly age groups (over 80 years old) and were not 
implemented nationwide in Portugal. Falls prevention actions in Portugal are sparse, conducted 
locally in some health centers (local impact) and they did not occur simultaneously, therefore it is 
not likely that such local actions would explain the accentuated turning points in the time trends of 
ASIR nationwide.  
After 2003, with the decrease of hormonal replacement therapy, the total number of anti-
osteoporotic packages sold were mainly bisphosphonates, suggesting that the massive increase in 
prescription of these medications was the intervention responsible for the change in the trends of 
ASIR.  
The study allowed the identification of a plausible intervention: the prescription of 
bisphosphonates. It does not postulate on the effectiveness of the treatment, with the quantification 
of prevented hip fractures by number of treated patients or the adverse effects of its use. However, 
it is a measure of quality, in the sense that patients at risk are receiving the attention for hip fracture 
prevention, with the prescription of the available medication. The rapidly increase of 
bisphosphonates sales can be the result of the Bone and Joint Decade actions, that raised awareness 
to prevention, translating in a higher amount of individuals protected and consequently a decrease 
of incidence rates.  
Other authors have reported decreased trends [1-6],  however, this study differ from all the 
others. Some identified linear trends which made the authors question the influence of 
bisphosphonates [4, 5]. In other studies where turning points in incidence rates were identified and 
related  to the bisphosphonates sales, the identifications was merely visual, with no used of 
adequate statistical methods [1, 2].  
Trends of hip fractures can be driven by interventions or by alterations in risk factors of the 
individuals. Due to the diversity of proposed factors that are associated with trend of hip fracture, 
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this study analyses the problem through different perspectives. Even after accounting for 
differences observed in birth cohorts, a decreasing pattern compatible with intervention was 
identified, in the period of study for women incidence rates. The cohort effect identified risk 
fluctuations in every year that Portugal suffered political or economic changes, with impact on 
population. 
An increased risk after the beginning of World War I, where the population suffered from a 
shortage of food supply and faced the Spanish flu, followed by one of the highest inflation seen in 
Europe. Situation aggravated in Portugal by a serious internal political instability. The next 
chronologic event in the history of Portugal, around 1930, with a change in the political regime had 
an influence in the health conditions of the population, already measured by higher birth and lower 
mortality rates, also reflected on the risk of hip fracture, with a decrease risk of fracture for birth 
cohorts born in this period. Portugal was totally dependent on importation, when in 1939, World 
War II begins, leaving the population once again under food restrictions, and the results reflect this 
with a new increase of risk observed in birth cohorts during this period. The next alteration, with a 
decrease in the risk is observed in the same period were Portugal receives financial aid through 
Marshall Plan.  
No one, of the scarce number of published paper using a methodology to study the impact of 
combined age, period and cohort effects reported similar results for cohort effects [7-10], which 
makes sense, since the quality of bone is a reflection of a life-time balance between formation and 
resorption occurring in bone tissue with improved results from adequate external conditions [11, 
12]. Therefore the results obtained in the Age-Period-Cohort (Chapter 4) are biological and 
historical plausible, and since the economic, social and political history differs from country to 
country it is expected that the relation with risk of fractures in the elderly is also different from 
country to country. On the other hand, the age effect is similar in all studies. Period effect is 
difficult to compare, because the studies that use the same methodology use different period. 
The study of hip fracture incidence rates as an indicator of preventive treatment, proved to be 
effective. Even after the identification of a cohort effect, there is a decrease in hip fracture rate in 
women. Regardless of no causal relationship being able to be attributed using ecological studies, 
the results from chapters 3 and 4, acknowledge important aspects that can be useful in public 
health. Population at risk of sustaining hip fracture is wide and diverse, any preventive action 
benefits from the information provided. The results also provide future lines of investigation. The 
economical constrains that the population is facing might lead to decrease of the number of anti-
osteoporotic medication sales, which can result in a possible increase in the trend, hence the 
importance of continuing the trend analysis. In addition, it would be also important to evaluate the 
trend of other type of fractures, since prolonged use of bisphosphonates have been associated with 
atypical femoral fractures as well as osteonecrosis of the jaw and are already being described as 
negative on other skeleton parts [13]. 
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The results regarding the study of quality of treatment after the fracture, were based on an 
outcome: in-hospital fatality.  
First, possible factors that could explain differences in-hospital fatality rates were explored, 
in the study presented in chapter 5. The results from a meta-regression analysis showed that the 
effect of economic variables should be taken into consideration when explaining differences in in-
hospital fatality rates observed in published studies. Variables related to allocation of medical 
resources were identified as having a positive impact on in-hospital fatality rates. Higher number of 
medical doctors and bed availability leads to a decrease of in-hospital fatality rates. These results 
are in accordance to the results obtain in the previous chapters, more health resources lead to better 
fitted population, or to a more prompted response to the treatment, and therefore to a better 
outcome if the fracture occurs. 
The quality framework proposed for the assessment of the quality of treatment, included 3 
levels: patients, hospitals and areas. The results identified that the individual characteristics’ of the 
patient (age, sex and severity of health conditions) and some variables related to procedures (time 
to surgery and treatment) have impact on the probability of dying in the hospital for the treatment 
of a hip fracture. Better health fitted population can face the treatment with a higher probability of 
surviving the hospitalization than less fitted population.  
In Portugal, hospitals that treat more than 50 hip fractures per year do not present 
differentiated effect on the probability of the patient dying while hospitalized, after the adjustment 
for patients, hospital and area characteristics’.The overall probability of dying did not present 
alteration in the time frame of the study. However, some hospitals presented significant 
improvements, and others the tendency to an aggravated effect in the study period. Factors that 
could help understand these changes overtime, such as changes in pre-operative and pos-operative 
treatment (early stabilization, nutritional assessment and treatment), should be further investigated. 
However, changes in procedures may difficult to evaluate nationwide, due to lack of available data. 
No area effect was identified; medical resources from the areas were the hospital is set were not 
determinant for the outcome. 
The methodology applied in chapter 6, was also applied in a study regarding hip fractures to 
determine the association between timing of surgery and in-hospital mortality, the results did not 
find evidence that the effect of delayed surgery on mortality was different across hospitals [14]. 
Hospital and regional differences in outcomes of hip fractures, were reported by a study in Finland 
[15], their approach also included only providers with more than 50 patients treated yearly. 
However, the methodological approach was simpler, even if the authors acknowledge the existence 
and benefit of more complex alternatives [16]. 
The results from chapter 5 and 6 can be interchangeable, chapter 5 shows that risk 
adjustment should take resources into consideration, chapter 6, using this knowledge shows that 
individual characteristics’, such as general health condition of the patient acts on the probability of 
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dying.  When lacking patient characteristics, such as in meta-analysis, in chapter 5, macro- 
economic variables that can act on health status of population seems to be a solution to explain a 
part of the observed variability.  
The restructuration that occurred during the period of the study in some hospitals of SNS 
(National Health System) with some fusions, based on aggregation of resources (human and 
material) will lead to an important need in the future; the assessment of the implications in the 
treatment of hip fractures.  
Another important global result, was the possible existence of a gender difference in the 
treatment of hip fractures, both in prevention and in treatment. Usually associated with women, that 
have higher risk due to the rapid bone loss after the menopause, men seem to be overlooked. The 
trend of hip fracture incidence rates is decreasing in women; women are usually the target 
population of anti-osteoporotic medication. However, men tend to have a worse outcome, even 
after adjustment for health status and treatment. With the increasing life-expectancy of men, 
osteoporotic fractures in men should be given more attention. 
Limitations of these studies are manly associated with data limitation. In spite of being a rich 
and important font of epidemiological data the National Hospital Discharge Register (NHDR) has 
some limitations, like the lack of information about the functional recovery of the patient at time of 
discharge, or more accurate information on surgical procedures, or even in the possibility of 
tracking the patient between hospitals.  
The results and methodology applied in this study were innovative, few published paper 
identified a marked turning point in the trend of hip fractures, compatible with intervention. No 
other paper, that showed the plausible effect of the history on the cohort effect of hip fractures 
trend could be identified. The use of macro-economic variables to explain the variation between in-
hospital fatality rates was not identified in no other published work. Finally, the multilevel 
approach, which is seldom applied to adjust the risk of unfavorable outcomes, showed that given 
some initial characteristics, acute care may not be as important as primary and preventive care in 
the treatment of hip fracture.  
This study is an extensive research on hip fracture treatment in Portugal, using a global 
perspective, with quality assessment before and after the fracture event. It allowed not only the 
general perspective of the treatment given within the study period but also the identification of 
some aspects that can be addressed in order to obtain improvement: medication, different birth 
cohort risk, general health of the population, conservative treatment. 
 
Chapter VII   
 
 121 
 
References 
[1] Fisher A, Martin J, Srikusalanukul W, Davis M. Bisphosphonate use and hip 
fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging 2010;5: 355-62. 
[2] Fisher AA, O'Brien ED, Davis MW. Trends in hip fracture epidemiology in 
Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 2009;45: 
246-53. 
[3] Korhonen N, Niemi S, Parkkari J, Sievanen H, Palvanen M, Kannus P. Continuous 
decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010. 
Osteoporos Int 2012. 
[4] Abrahamsen B, Vestergaard P. Declining incidence of hip fractures and the extent 
of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int 2010;21: 373-80. 
[5] Leslie WD, Sadatsafavi M, Lix LM, Azimaee M, Morin S, Metge CJ, Caetano P. 
Secular decreases in fracture rates 1986-2006 for Manitoba, Canada: a population-based analysis. 
Osteoporos Int 2011;22: 2137-43. 
[6] Adams AL, Shi J, Takayanagi M, Dell RM, Funahashi TT, Jacobsen SJ. Ten-year 
hip fracture incidence rate trends in a large California population, 1997-2006. Osteoporos Int 2012. 
[7] Langley J, Samaranayaka A, Davie G, Campbell AJ. Age, cohort and period effects 
on hip fracture incidence: analysis and predictions from New Zealand data 1974-2007. Osteoporos 
Int 2011;22: 105-11. 
[8] Rosengren B, Ahlborg H, Mellstrom D, Nilsson J, Bjork J, Karlsson M. Secular 
trends in Swedish hip fractures 1987-2002: birth cohort and period effects. Epidemiology 2012;23: 
623-30. 
[9] Evans JG, Seagroatt V, Goldacre MJ. Secular trends in proximal femoral fracture, 
Oxford record linkage study area and England 1968-86. J Epidemiol Community Health 1997;51: 
424-9. 
[10] Samelson EJ, Zhang Y, Kiel DP, Hannan MT, Felson DT. Effect of birth cohort on 
risk of hip fracture: age-specific incidence rates in the Framingham Study. Am J Public Health 
2002;92: 858-62. 
[11] Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, 
Weaver C. Peak bone mass. Osteoporos Int 2000;11: 985-1009. 
[12] Hunter DJ, Sambrook PN. Bone loss. Epidemiology of bone loss. Arthritis Res 
2000;2: 441-5. 
[13] Orozco C, Maalouf NM. Safety of bisphosphonates. Rheum Dis Clin North Am 
2012;38: 681-705. 
Chapter VII   
 
 122 
[14] Librero J, Peiro S, Leutscher E, Merlo J, Bernal-Delgado E, Ridao M, Martinez-
Lizaga N, Sanfelix-Gimeno G. Timing of surgery for hip fracture and in-hospital mortality: a 
retrospective population-based cohort study in the Spanish National Health System. BMC Health 
Serv Res 2012;12: 15. 
[15] Sund R, Juntunen M, Luthje P, Huusko T, Hakkinen U. Monitoring the 
performance of hip fracture treatment in Finland. Ann Med 2011;43 Suppl 1: S39-46. 
[16] Peltola M, Juntunen M, Hakkinen U, Rosenqvist G, Seppala TT, Sund R. A 
methodological approach for register-based evaluation of cost and outcomes in health care. Ann 
Med 2011;43 Suppl 1: S4-13. 
 
 
 
